St. Jude Medical (STJ) 10-Q 7 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Oct. 01, 2016	Nov. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 1, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	ST JUDE MEDICAL INC
Entity Central Index Key	203,077
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		285,716,462

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Income Statement [Abstract]
Net sales	$ 1,499	$ 1,339	$ 4,509	$ 4,094
Cost of sales:
Cost of sales before special charges	470	408	1,444	1,220
Special charges	25	17	34	24
Total cost of sales	495	425	1,478	1,244
Gross profit	1,004	914	3,031	2,850
Selling, general and administrative expense	481	413	1,474	1,290
Research and development expense	183	161	563	499
Amortization of intangible assets	47	23	139	71
Special charges	7	23	28	57
Operating profit	286	294	827	933
Interest income	0	(1)	(1)	(2)
Interest expense	39	22	119	63
Other (income) expense	2	12	58	9
Other expense, net	41	33	176	70
Earnings before income taxes and noncontrolling interest	245	261	651	863
Income tax expense	33	46	106	110
Net earnings before noncontrolling interest	212	215	545	753
Less: Net loss attributable to noncontrolling interest	0	0	0	(14)
Net earnings attributable to St. Jude Medical, Inc.	$ 212	$ 215	$ 545	$ 767
Net earnings per share attributable to St. Jude Medical, Inc.:
Basic (USD per share)	$ 0.74	$ 0.76	$ 1.92	$ 2.72
Diluted (USD per share)	0.73	0.75	1.89	2.68
Cash dividends declared per share (USD per share)	$ 0.31	$ 0.29	$ 0.93	$ 0.87
Weighted average shares outstanding:
Basic (in shares)	285.2	282.2	284.3	282.1
Diluted (in shares)	290	286.3	288.2	286.3

Condensed Consolidated Stateme3

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Statement of Comprehensive Income [Abstract]
Net earnings before noncontrolling interest	$ 212	$ 215	$ 545	$ 753
Other comprehensive income (loss), net of tax
Unrealized gain (loss) on available-for-sale securities, net of tax (expense) benefit $1, $4, $1 and $6, respectively	(1)	(8)	0	(11)
Unrealized gain (loss) on derivative financial instruments, net of tax (expense) benefit of $-, $2, $16 and ($1), respectively	0	(11)	(34)	1
Foreign currency translation adjustment	3	(25)	34	(122)
Other comprehensive income (loss), net of tax	2	(44)	0	(132)
Total comprehensive income before noncontrolling interest	214	171	545	621
Total comprehensive loss attributable to noncontrolling interest	0	0	0	(14)
Total comprehensive income attributable to St. Jude Medical, Inc.	$ 214	$ 171	$ 545	$ 635

Condensed Consolidated Stateme4

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Statement of Comprehensive Income [Abstract]
Tax (expense) benefit on related to increase (decrease) in accumulated gain (loss) from unrealized gain (loss) on available-for-sale securities	$ 1	$ 4	$ 1	$ 6
Tax (expense) benefit on related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges	$ 0	$ 2	$ 16	$ (1)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Oct. 01, 2016	Jan. 02, 2016
ASSETS
Cash and cash equivalents	$ 394	$ 667
Accounts receivable, less allowance for doubtful accounts of $49 and $46 at October 1, 2016 and January 2, 2016, respectively	1,290	1,237
Finished goods	555	609
Work in process	109	102
Raw materials	246	198
Inventories	910	909
Other current assets	222	269
Total current assets	2,816	3,082
Property, plant and equipment, at cost	2,942	2,767
Less: Accumulated depreciation	(1,606)	(1,447)
Net property, plant and equipment	1,336	1,320
Goodwill	5,678	5,651
Intangible assets, net	2,108	2,226
Other assets	603	621
TOTAL ASSETS	12,541	12,900
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current debt obligations	371	1,163
Accounts payable	232	201
Income taxes payable	48	201
Other current liabilities	806	901
Total current liabilities	1,457	2,466
Long-term debt	5,403	5,229
Other liabilities	1,195	1,163
Total liabilities	8,055	8,858
Commitments and Contingencies
Shareholders’ Equity
Preferred stock ($1.00 par value; 25,000,000 shares authorized; none outstanding)	0	0
Common stock ($0.10 par value; 500,000,000 shares authorized; 285,600,918 and 283,450,374 shares issued and outstanding at October 1, 2016 and January 2, 2016, respectively)	29	28
Additional paid-in capital	311	148
Retained earnings	4,491	4,211
Accumulated other comprehensive income (loss)	(345)	(345)
Total shareholders’ equity	4,486	4,042
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 12,541	$ 12,900

Condensed Consolidated Balance6

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Oct. 01, 2016	Jan. 02, 2016
Statement of Financial Position [Abstract]
Accounts receivable allowance for doubtful accounts	$ 49	$ 46
Preferred stock, par value (USD per share)	$ 1	$ 1
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (USD per share)	$ 0.1	$ 0.1
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	285,600,918	283,450,374
Common stock, shares outstanding	285,600,918	283,450,374
Commitments and Contingencies

Condensed Consolidated Stateme7

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015
OPERATING ACTIVITIES
Net earnings before noncontrolling interest	$ 545	$ 753
Adjustments to reconcile net earnings before noncontrolling interest to net cash from operating activities:
Depreciation of property, plant and equipment	175	162
Amortization of intangible assets	139	71
Stock-based compensation	83	55
Deferred income taxes	(58)	(18)
Other, net	110	(67)
Changes in operating assets and liabilities, net of business combinations:
Accounts receivable	(17)	(40)
Inventories	(24)	(85)
Other current and noncurrent assets	21	17
Accounts payable and accrued expenses	28	(5)
Income taxes payable	(97)	9
Net cash provided by operating activities	905	852
INVESTING ACTIVITIES
Purchases of property, plant and equipment	(189)	(124)
Business combination payments, net of cash acquired	(21)	0
Proceeds from sale of investments	0	20
Other investing activities, net	(5)	(12)
Net cash used in investing activities	(215)	(116)
FINANCING ACTIVITIES
Proceeds from exercise of stock options and stock issued, net	73	135
Excess tax benefits from stock issued under employee stock plans	9	17
Common stock repurchased, including related costs	0	(500)
Dividends paid	(258)	(240)
Issuances (payments) of commercial paper borrowings, net	(408)	451
Proceeds from debt	500	1,672
Payments of debt	(759)	(925)
Purchase of shares from noncontrolling interest	0	(173)
Payment of contingent consideration	(125)	0
Payments of debt issue costs and commitment fees	0	(33)
Other financing activities, net	(7)	(8)
Net cash provided by (used in) financing activities	(975)	396
Effect of currency exchange rate changes on cash and cash equivalents	12	(39)
Net increase (decrease) in cash and cash equivalents	(273)	1,093
Cash and cash equivalents at beginning of period	667	1,442
Cash and cash equivalents at end of period	$ 394	$ 2,535

Basis Of Presentation

Basis Of Presentation	9 Months Ended
	Oct. 01, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis Of Presentation	BASIS OF PRESENTATION Principles of Consolidation: The accompanying unaudited Condensed Consolidated Financial Statements of St. Jude Medical, Inc. (St. Jude Medical or the Company) have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (U.S. generally accepted accounting principles) for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s consolidated results of operations, financial position and cash flows. The Condensed Consolidated Balance Sheet at January 2, 2016 was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and footnotes. Actual results could differ from those estimates. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and footnotes included in its Current Report on Form 8-K filed with the SEC on June 7, 2016 for the fiscal year ended January 2, 2016 . The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, and other entities for which St. Jude Medical has a controlling financial interest. Effective January 1, 2016, the Company's Board of Directors appointed a new President and Chief Executive Officer whom the Company has determined to be its Chief Operating Decision Maker. During the first quarter of 2016, the Company changed its sales reporting to closely align with how it manages the business in five key areas: Traditional Cardiac Rhythm Management, Heart Failure, Atrial Fibrillation, Cardiovascular and Neuromodulation. The Company continues to operate as a single operating segment. Reclassifications: Certain prior period amounts have been reclassified to conform to current year presentation. Fiscal Year: We utilize a 52/53-week fiscal year ending on the Saturday nearest December 31st. Each of the three-and nine month periods ended October 1, 2016 and October 3, 2015 included 13 weeks and 39 weeks, respectively. New Accounting Pronouncements: The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the Company's financial statements or disclosures. Standard Description Required adoption timing and approach Impact of adoption or other significant matters Standards recently adopted Accounting Standards Update (ASU) No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis The standard affects both the variable interest entity and voting interest entity consolidation models. Annual and interim periods beginning after December 15, 2015, with either retrospective or modified retrospective application permitted. Early adoption is permitted. The Company adopted this ASU in the quarter ended April 2, 2016, using the modified retrospective method. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2015-05, Intangibles--Goodwill and Other--Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement The standard provides guidance to customers about how to account for cloud computing arrangements when such arrangements include software licenses. Annual and interim periods beginning after December 15, 2015, with either prospective or retrospective application permitted. Early adoption was permitted. The Company adopted this ASU in the quarter ended April 2, 2016, using the prospective method. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory The standard requires that inventory within the scope of the guidance be measured at the lower of cost or net realizable value. Annual and interim periods beginning after December 15, 2016, with prospective application required. Early adoption is permitted. The Company adopted this ASU in the quarter ended April 2, 2016. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments The update includes amendments to eight specific cash flow presentation matters, including contingent consideration payments after a business combination. Annual and interim periods beginning after December 15, 2017, with retrospective application required. Early adoption is permitted. The Company adopted this ASU in the interim period ended October 1, 2016. The adoption did not have a material impact on the Company's cash flows. Standards not yet adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will supersede the current revenue recognition requirements. Refer to ASU No. 2015-14 regarding the adoption timing. Either retrospective or modified retrospective application is permitted. The Company plans to adopt this ASU for interim and annual periods beginning after December 15, 2017. The Company is evaluating its approach to the adoption and the potential impact to its results of operations and financial position. ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date The standard defers the effective date of ASU No. 2014-09 to annual and interim periods beginning after December 15, 2017. Early adoption is permitted only as of annual and interim reporting periods beginning after December 15, 2016. Not applicable. Not applicable. ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Among other things, the standard requires certain equity investments to be measured at fair value with changes in fair value recognized in net income, simplifies the impairment assessment of equity investments without readily determinable fair values, and eliminates certain disclosure requirements. Annual and interim periods beginning after December 15, 2017. Early adoption of certain guidance is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position. ASU No. 2016-02, Leases (Topic 842) Among other things, the standard requires recognition of a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position for virtually all leases where we are the lessee. Annual and interim periods beginning after December 15, 2018, with modified retrospective application required. Early adoption is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position. ASU No. 2016-09, Compensation--Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The areas for simplification in this standard involve several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. Annual and interim periods beginning after December 15, 2016, with certain aspects requiring modified retrospective transition, retrospective application, and/or prospective application. Early adoption is permitted if all aspects are adopted simultaneously. The Company is evaluating the timing of adoption and the potential impact to its results of operations, financial position and cash flows. ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Among other things, the standard clarifies the principle for determining whether a good or service is “separately identifiable” from other promises in the contract and, therefore, should be accounted for separately. It also clarifies that entities are not required to identify promised goods or services that are immaterial in the context of the contract. Refer to ASU No. 2015-14 regarding the adoption timing. Either retrospective or modified retrospective application is permitted. The Company plans to adopt this ASU for interim and annual periods beginning after December 15, 2017. The Company is evaluating its approach to the adoption and the potential impact to its results of operations and financial position. ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory The standard requires the income tax consequences of an intra-entity transfer of an asset other than inventory to be recognized when the transfer occurs. Annual and interim periods beginning after December 15, 2017, with modified retrospective application required. Early adoption is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position, which is expected to be material.

Debt

Debt	9 Months Ended
	Oct. 01, 2016
Debt Disclosure [Abstract]
Debt	DEBT The carrying value of the Company’s debt, including debt issuance costs, discounts or premiums consisted of the following (in millions): October 1, 2016 January 2, 2016 Term Loan Due 2020 $ 2,336 $ 2,093 2016 Senior Notes — 500 2018 Senior Notes 497 496 2020 Senior Notes 497 496 2023 Senior Notes 893 892 2025 Senior Notes 495 494 2043 Senior Notes 689 689 Yen-denominated Senior Notes Due 2017 81 68 Yen-denominated Senior Notes Due 2020 126 106 Yen-denominated credit facilities 64 54 Commercial paper borrowings 96 504 Total debt 5,774 6,392 Less: current debt obligations 371 1,163 Long-term debt $ 5,403 $ 5,229 Contractual maturities of the Company's debt for the next five fiscal years and thereafter, excluding any debt issuance costs, discounts or premiums, as of October 1, 2016 were as follows (in millions): Remainder of 2016 2017 2018 2019 2020 After 2020 Future minimum principal payments $ 128 $ 275 $ 598 $ 227 $ 2,481 $ 2,100 During the first nine months of 2016, the Company repaid its $500 million principal amount of 5 -year, 2.500% unsecured senior notes due 2016, made net commercial paper payments of $408 million and drew the remaining $500 million of its 5 -year, $2.6 billion unsecured term loan due 2020 (Term Loan Due 2020) to refinance existing indebtedness and for general corporate purposes. The Company also made quarterly principal payments totaling $92 million for the nine months ended October 1, 2016 and prepaid an additional $167 million on its Term Loan Due 2020. Additionally, during the nine months ended October 1, 2016, the Company's yen-denominated credit facility that expired in March 2016 for 3.25 billion Japanese Yen (the equivalent of $32 million as of October 1, 2016 ) was automatically extended for a one -year period bearing interest at Yen LIBOR plus 0.250% , and the Company's yen-denominated credit facility that expired in June 2016 for 3.25 billion Japanese Yen (the equivalent of $32 million as of October 1, 2016 ) was automatically extended for a one -year period bearing interest at Yen LIBOR plus 0.270% .

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
	Oct. 01, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	COMMITMENTS AND CONTINGENCIES Securities and Other Shareholder Litigation December 2012 Securities Litigation: On December 7, 2012, a putative securities class action lawsuit was filed in federal district court in Minnesota against the Company and an officer (collectively, the defendants) for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the defendants between October 17, 2012 and November 20, 2012. The complaint, which sought unspecified damages and other relief as well as attorneys' fees, challenges the Company’s disclosures concerning its high voltage cardiac rhythm lead products during the purported class period. On December 10, 2012, a second putative securities class action lawsuit was filed in federal district court in Minnesota against the Company and certain officers for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the Company between October 19, 2011 and November 20, 2012. The second complaint alleged similar claims and sought similar relief. In March 2013, the Court consolidated the two cases and appointed a lead counsel and lead plaintiff. A consolidated amended complaint was served and filed in June 2013, alleging false or misleading representations made during the class period extending from February 5, 2010 through November 7, 2012. In September 2013, the defendants filed a motion to dismiss the consolidated amended complaint. On March 10, 2014, the Court ruled on the motion to dismiss, denying the motion in part and granting the motion in part. On October 7, 2014, the lead plaintiff filed a second amended complaint. Like the original consolidated amended complaint, the plaintiffs did not assert any specific amount of compensation in the second amended complaint. The Court granted class certification on December 22, 2015. On May 24, 2016, the parties agreed to resolve the case, pending notification to class members and subject to court approval. Under the settlement, the Company agreed to make a payment of $39.25 million to resolve all of the class claims and recorded a charge of that amount during the second quarter of 2016. On July 13, 2016, the Court issued an order preliminarily approving the settlement. Concurrent with the recording of the loss, the Company also recognized probable insurance recoveries of $39.25 million . The hearing on final settlement approval is scheduled for November 9, 2016. Abbott Merger Lawsuits: On May 2, 2016, a shareholder of the Company filed a purported class action lawsuit in Ramsey County, Minnesota, captioned Silverman v. St. Jude Medical, Inc., et al., 62-CV-16-2872 alleging that the Company's directors breached their fiduciary duties in connection with the proposed merger contemplated by the Company and Abbott Laboratories (Abbott) (the Proposed Transaction). On May 26, 2016, a second action entitled Larkin v. Starks, et al., 62-CV-16-3367, was filed in the same court alleging substantially similar claims. On July 5, 2016, plaintiffs in the two actions jointly filed an Amended Shareholder class and Derivative Action Complaint (the Amended Complaint). Plaintiffs’ Amended Complaint asserts that the Company’s directors breached their fiduciary duties by conducting a flawed sale process, failing to maximize shareholder value, and publishing false or misleading disclosure materials relating to the Proposed Transaction, and that the Abbott defendants aided and abetted those breaches. The Amended Complaint asserts direct and/or derivative claims for breach of fiduciary duty, corporate waste and abuse of control under Minnesota Statute § 302A.467. Plaintiffs seek, among other things, to enjoin the Proposed Transaction and an order directing defendants to account to plaintiffs for all damages allegedly suffered by the putative class and damages allegedly incurred by the Company in connection with the Proposed Transaction. On August 3, 2016, a third action entitled Gross v. Starks, et al., 62-CV-16-4581, was filed in Ramsey County, Minnesota, containing allegations similar to those in the Silverman Amended Complaint. This action was consolidated with the two previously filed actions. On June 30, 2016, a shareholder of the Company filed a purported class action lawsuit in the United States District Court for the District of Minnesota, captioned Rosenfeld v. St. Jude Medical, Inc., et al., 16-cv-02275-WMW-FLN, alleging that the Company and its directors violated Section 14(a) of the Securities Exchange Act of 1934, SEC Rule 14a-9, and Minnesota Statute §§ 80A.68 and 80A.76, and that the Company’s directors violated Section 20(a) of the Exchange Act, by filing a Form S-4 with the SEC that contained false or misleading statements regarding the Proposed Transaction. Plaintiff seeks, among other things, to enjoin the Proposed Transaction or, if consummated, an order rescinding it or awarding actual and punitive damages to Plaintiff and the putative class. The Company and its directors intend to vigorously defend against the allegations in these actions involving the Proposed Transaction. The Company believes that a material loss is remote. Refer to Note 11 for a discussion of the Proposed Transaction. Regulatory Matters The U.S. Food and Drug Administration (FDA) inspected the Company’s manufacturing facility in Atlanta, Georgia, where the Company manufactures its CardioMEMS™ HF system, at various times between June 8 to June 26, 2015. On July 6, 2015, the FDA issued a Form 483 identifying certain observed non-conformity with current Good Manufacturing Practice at the facility. Following the receipt of the Form 483, the Company provided written responses to the FDA detailing proposed corrective actions and immediately initiated efforts to address the FDA’s observations of non-conformity. The Company subsequently received a warning letter dated September 30, 2015 from the FDA relating to these non-conformities. Since the completion of the FDA inspection, the Company has provided and will continue to provide the FDA with regular updates. The Company has fully-integrated this former CardioMEMS standalone facility into St. Jude Medical's quality systems. During July 2016, the FDA conducted a follow-up inspection at the Atlanta facility. On July 28, 2016, the FDA issued a Form 483 identifying additional observed non-conformities with current Good Manufacturing Practice at the facility. The Company has worked to remediate these observations. There has been no inspection subsequent to the issuance of the Form 482 and no other further action to date by the FDA. The warning letter is specific to the Atlanta facility and does not impact any of the Company’s other manufacturing facilities. The warning letter does not identify any specific concerns regarding the performance of, or indicate the need for any field or other action regarding, the CardioMEMS™HF system product or any other St. Jude Medical product. The Company will continue manufacturing and shipping product from the Atlanta facility, and customer orders are not expected to be impacted while the Company works to resolve the FDA’s concerns. The Company takes these matters seriously, will respond timely and fully to the FDA’s requests, and believes that the FDA’s concerns will be resolved without a material impact on the Company’s financial results. Intellectual Property Matters On October 26, 2016, the Regents of the University of California filed a patent infringement action against the Company in the United States District Court for the Northern District of California alleging that two U.S. patents owned by the Regents of the University of California are infringed by certain of our catheters and other devices used to treat atrial fibrillation. The Company has not recorded an expense related to any potential damages in connection with this matter because any potential loss is not probable or reasonably estimable. Because, based on the Company’s historical experience, the amount ultimately paid, if any, often does not bear any relationship to the amount claimed, the Company cannot reasonably estimate a loss or range of loss, if any, that may result from this matter. Product Warranties The Company offers a warranty on various products, the most significant of which relate to tachycardia implantable cardioverter defibrillator (ICD) and pacemaker systems. The Company estimates the costs it expects to incur under its warranties and records a liability for such costs at the time the product is sold. Factors that affect the Company's warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company regularly assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary. Changes in the Company’s product warranty liability during the three and nine months ended October 1, 2016 and October 3, 2015 were as follows (in millions): Three Months Ended Nine Months Ended October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Balance at beginning of period $ 25 $ 29 $ 31 $ 35 Warranty expense (benefit) recognized 4 — 5 (4 ) Warranty credits issued (4 ) (1 ) (11 ) (3 ) Balance at end of period $ 25 $ 28 $ 25 $ 28

Special Charges

Special Charges	9 Months Ended
	Oct. 01, 2016
Special Charges [Abstract]
Special Charges	SPECIAL CHARGES The Company recognizes certain transactions and events as special charges in its Condensed Consolidated Financial Statements . These charges (such as restructuring charges, impairment charges, certain legal settlements or product field action costs and litigation costs) result from facts and circumstances that vary in frequency and impact on the Company's results of operations. 2016 Initiatives During the fourth quarter of 2015, the Company initiated restructuring activities to drive cross-functional synergies (the 2016 Initiatives). The 2016 Initiatives include enhancing focus on programs that will strengthen its strategic objectives, driving productivity enhancements and incurring costs to fully integrate its recent acquisitions. During 2015, the Company incurred charges primarily related to severance and other termination benefits. During the first quarter of 2016, the Company incurred additional charges related to severance and other termination benefits, contract termination costs and fixed asset write-offs, primarily associated with the closure of Thoratec Corporation (Thoratec) facilities as the Company continues to integrate the acquisition. During the second quarter of 2016, the Company incurred additional charges related to severance and other termination benefits, distributor contract terminations and other Thoratec-related contract terminations. During the third quarter of 2016, the Company incurred additional charges related to contract terminations and other exit costs, severance and other termination benefits and fixed asset write-offs, primarily associated with the continued closure of its Thoratec facilities and a U.S. based research facility. The Company currently expects to incur approximately $5 million to $10 million during the remainder of 2016 to complete the plan, but may incur additional charges in future periods. A summary of the activity related to the 2016 Initiatives accrual is as follows (in millions): Employee Inventory Fixed Other Restructuring Costs Total Balance at January 3, 2015 $ — $ — $ — $ — $ — Cost of sales special charges 9 1 1 1 12 Special charges 22 — — — 22 Non-cash charges used — (1 ) (1 ) — (2 ) Cash payments (2 ) — — (1 ) (3 ) Balance at January 2, 2016 29 — — — 29 Cost of sales special charges — 2 1 1 4 Special charges 11 — 4 5 20 Non-cash charges used — (2 ) (5 ) — (7 ) Cash payments (32 ) — — (5 ) (37 ) Balance at April 2, 2016 8 — — 1 9 Cost of sales special charges — — — 2 2 Special charges 6 — — 4 10 Cash payments (6 ) — — (4 ) (10 ) Balance at July 2, 2016 8 — — 3 11 Cost of sales special charges — — — 2 2 Special charges 2 — 1 1 4 Non-cash charges used — — (1 ) — (1 ) Cash payments (3 ) — — (3 ) (6 ) Balance at October 1, 2016 $ 7 $ — $ — $ 3 $ 10 Manufacturing and Supply Chain Optimization Plan During 2014, the Company initiated the Manufacturing and Supply Chain Optimization Plan to leverage economies of scale, streamline distribution methods, drive process improvements through global synergies, balance plant utilization levels, centralize certain vendor relationships and reduce overall costs. During 2015, the Company incurred charges primarily related to severance and other termination benefits, contract termination costs and fixed asset write-offs. These costs included charges associated with the elimination of certain operational, quality and hardware development activities at a research and development facility, continued exit costs related to a facility closure in the United States and software development assets no longer expected to be utilized. During the first, second and third quarters of 2016, the Company incurred additional charges primarily related to continued exit costs associated with a facility closure in the United States. Material charges are not expected in future periods as the Manufacturing and Supply Chain Optimization Plan is now complete. A summary of the activity related to the Manufacturing and Supply Chain Optimization Plan accrual is as follows (in millions): Employee Inventory Fixed Other Restructuring Costs Total Balance at January 3, 2015 $ 14 $ — $ — $ 6 $ 20 Cost of sales special charges 4 3 15 7 29 Special charges 20 — — 29 49 Non-cash charges used — (3 ) (15 ) — (18 ) Cash payments (27 ) — — (35 ) (62 ) Balance at January 2, 2016 11 — — 6 17 Cost of sales special charges — — — 1 1 Cash payments (3 ) — — (6 ) (9 ) Balance at April 2, 2016 8 — — 1 9 Cost of sales special charges — — — 1 1 Special charges — — — 1 1 Cash payments (3 ) — — (2 ) (5 ) Balance at July 2, 2016 5 — — 1 6 Special charges — — — 1 1 Cash payments (2 ) — — (1 ) (3 ) Balance at October 1, 2016 $ 3 $ — $ — $ 1 $ 4 2012 Business Realignment Plan During 2012, the Company realigned its product divisions into two new operating divisions: the Implantable Electronic Systems Division (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes have been part of a comprehensive plan to accelerate the Company's growth, reduce costs, leverage economies of scale and increase investment in product development. During 2014, the Company announced additional organizational changes including the combination of its Implantable Electronic Systems Division and Cardiovascular and Ablation Technologies Division, resulting in an integrated research and development (R&D) organization and a consolidation of manufacturing and supply chain operations worldwide. During 2015, the Company incurred additional charges primarily related to severance and other termination benefits and other restructuring costs, including contract termination costs, asset relocation expenses and other exit costs predominately associated with the facility closure in Europe. During the first quarter of 2016, the Company reassessed the remaining accrual balance and determined that some of the previously recorded accrual balances were no longer necessary. Additionally, during the third quarter of 2016, the Company revised estimates for employee termination costs, recognizing a special benefit. Additionally, the Company recognized a special benefit for salvaged inventory components during the third quarter of 2016. No additional charges are expected in future periods as the 2012 Business Realignment Plan is complete. A summary of the activity related to the 2012 Business Realignment Plan accrual is as follows (in millions): Employee Termination Costs Inventory Charges Fixed Asset Charges Other Restructuring Costs Total Balance at January 3, 2015 $ 26 $ — $ — $ 12 $ 38 Cost of sales special charges 2 3 — — 5 Special charges 2 — 2 5 9 Non-cash charges used — (3 ) (2 ) — (5 ) Cash payments (25 ) — — (10 ) (35 ) Foreign exchange rate impact (2 ) — — — (2 ) Balance at January 2, 2016 3 — — 7 10 Cost of sales special charges — (1 ) — (1 ) (2 ) Non-cash charges used — 1 — — 1 Balance at April 2, 2016 3 — — 6 9 Cash payments (1 ) — — — (1 ) Balance at July 2, 2016 2 — — 6 8 Cost of sales special charges — (2 ) — — (2 ) Special charges (1 ) — — — (1 ) Non-cash charges used — 2 — — 2 Cash payments (1 ) — — — (1 ) Balance at October 1, 2016 $ — $ — $ — $ 6 $ 6 Other Special Charges Intangible asset impairment charges: During the third quarter of 2015, the Company recognized a $2 million impairment charge associated with a customer relationship intangible asset (see Note 8). Legal settlements: During the third quarter of 2016, the Company recognized charges of $3 million primarily to evaluate allegations made by third parties about the safety and security of the Company's implantable cardiac rhythm management devices, initiate litigation against certain third parties related to those allegations and evaluate claims in a putative class action lawsuit asserting claims related to the safety and security of those devices. The putative class action has not yet been served. The Company also recognized net legal settlement gains of $19 million associated with four separate legal cases during the first nine months of 2016. Additionally, the Company recognized a legal settlement loss related to the December 2012 Securities Litigation and concurrently recognized insurance recoveries in the same amount during the first nine months of 2016 (see Note 3). During the third quarter of 2015, the Company recognized a $1 million charge related to an unfavorable judgment for a product liability claim. During the first nine months of 2015, this charge was fully offset by $10 million in insurance recoveries recognized by the Company as a special benefit in connection with the March 2010 Securities Class Action Litigation. Product field action costs and litigation costs: During the first nine months of 2016 and 2015, the Company recognized approximately $6 million and $14 million , respectively, of litigation charges for expected future probable and estimable legal costs associated with outstanding legal matters related to the Company's product field actions. Charges in excess of the amounts accrued are reasonably possible and depend on a number of factors, such as the type of claims received and the cost to defend. During the third quarter and first nine months of 2016, the Company recognized $25 million and $28 million , respectively, of product field action costs. The Company initiated an advisory letter to physicians for patients implanted with certain tachycardia cardiac rhythm management devices that were identified as having a potential premature battery depletion issue that could, on rare occasions, result in necessary treatment not being provided. In connection with this advisory, the Company recognized charges of $26 million to cost of sales special charges related to product field action costs, primarily for estimated scrapped inventory and costs for providing remote monitoring to patients under the advisory during the third quarter of 2016. Charges in excess of the accrual are reasonably possible and depend on a number of factors, such as the number of physicians requesting remote monitoring. During the first nine months of 2016, the Company also initiated an advisory letter to physicians for patients implanted with certain ICD devices that were identified as having a potential therapy anomaly resulting in a lack of necessary treatment. As a result, the Company recognized charges of $5 million to cost of sales special charges primarily for estimated scrapped inventory and warranty costs during the first nine months of 2016. Partially offsetting these charges, the Company recognized a $1 million benefit and a $3 million benefit during the third quarter and first nine months of 2016, respectively, to cost of sales special charges for salvaged inventory components related to an advisory action initiated in 2014. During the fourth quarter of 2016, the Company initiated an advisory letter to physicians participating in an investigational device exemption study for patients implanted with certain leadless bradycardia cardiac rhythm management devices that were identified as having a potential premature battery depletion issue that could, on rare occasions, result in necessary treatment not being provided. As a result, the Company expects to recognize charges relating to scrapped inventory and intangible assets, which will be partially offset by reductions in contingent consideration liabilities. During the first nine months of 2015, the Company recognized a $7 million benefit to cost of sales special charges , of which $5 million related to salvaged inventory components associated with the same advisory action initiated in 2014 and $2 million related to lower than expected direct recall costs associated with a 2012 voluntary product field action related to certain neuromodulation implantable pulse generator charging systems. Other restructuring-related charges: The Company also recognized other restructuring-related charges of $3 million during the first nine months of 2016.

Net Earnings Per Share

Net Earnings Per Share	9 Months Ended
	Oct. 01, 2016
Earnings Per Share [Abstract]
Net Earnings Per Share	NET EARNINGS PER SHARE The table below sets forth the computation of basic and diluted net earnings per share attributable to St. Jude Medical, Inc. (in millions, except per share amounts): Three Months Ended Nine Months Ended October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Numerator: Net earnings attributable to St. Jude Medical, Inc. $ 212 $ 215 $ 545 $ 767 Denominator: Basic weighted average shares outstanding 285.2 282.2 284.3 282.1 Dilution associated with stock-based compensation plans 4.8 4.1 3.9 4.2 Diluted weighted average shares outstanding 290.0 286.3 288.2 286.3 Basic net earnings per share attributable to St. Jude Medical, Inc. $ 0.74 $ 0.76 $ 1.92 $ 2.72 Diluted net earnings per share attributable to St. Jude Medical, Inc. $ 0.73 $ 0.75 $ 1.89 $ 2.68 Anti-dilutive shares of common stock excluded from diluted net earnings per share attributable to St. Jude Medical, Inc. — 2.6 4.1 3.1

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Information	9 Months Ended
	Oct. 01, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Information	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) AND SUPPLEMENTAL EQUITY INFORMATION The tables below present the changes in each component of accumulated other comprehensive income, net of tax, including other comprehensive income and reclassifications out of accumulated other comprehensive income into net earnings for the three and nine months ended October 1, 2016 and October 3, 2015 , respectively (in millions): Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the three months ended sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of July 2, 2016 $ 4 $ (23 ) $ (328 ) $ (347 ) Other comprehensive income (loss) before reclassifications (1 ) (4 ) 3 (2 ) Amounts reclassified to net earnings from accumulated other comprehensive income — 4 — 4 Other comprehensive income (loss) (1 ) — 3 2 Accumulated other comprehensive income (loss) as of October 1, 2016 $ 3 $ (23 ) $ (325 ) $ (345 ) Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the nine months ended sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of January 2, 2016 $ 3 $ 11 $ (359 ) $ (345 ) Other comprehensive income (loss) before reclassifications — (34 ) 34 — Amounts reclassified to net earnings from accumulated other comprehensive income — — — — Other comprehensive income (loss) — (34 ) 34 — Accumulated other comprehensive income (loss) as of October 1, 2016 $ 3 $ (23 ) $ (325 ) $ (345 ) Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the three months ended October 3, 2015 sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of July 4, 2015 $ 12 $ 15 $ (288 ) $ (261 ) Other comprehensive income (loss) before reclassifications (1 ) (7 ) (25 ) (33 ) Amounts reclassified to net earnings from accumulated other comprehensive income (7 ) (4 ) — (11 ) Other comprehensive income (loss) (8 ) (11 ) (25 ) (44 ) Accumulated other comprehensive income (loss) as of October 3, 2015 $ 4 $ 4 $ (313 ) $ (305 ) Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the nine months ended October 3, 2015 sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of January 3, 2015 $ 15 $ 3 $ (191 ) $ (173 ) Other comprehensive income (loss) before reclassifications — 9 (122 ) (113 ) Amounts reclassified to net earnings from accumulated other comprehensive income (11 ) (8 ) — (19 ) Other comprehensive income (loss) (11 ) 1 (122 ) (132 ) Accumulated other comprehensive income (loss) as of October 3, 2015 $ 4 $ 4 $ (313 ) $ (305 ) Income taxes are not provided for foreign translation related to permanent investments in international subsidiaries. Reclassification adjustments are made to avoid double counting items in comprehensive income that are also recorded as part of net earnings. The following table provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Condensed Consolidated Statements of Earnings during the three and nine months ended October 1, 2016 and October 3, 2015 , respectively (in millions): Details about Amount reclassified from accumulated other comprehensive income accumulated other Three Months Ended Nine Months Ended comprehensive income components October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Statements of Earnings Classification Unrealized (gain) loss on available-for-sale securities: (Gain) loss on sale of available-for-sale securities $ — $ (11 ) $ — $ (18 ) Other (income) expense Tax effect — 4 — 7 Income tax expense Net of tax $ — $ (7 ) $ — $ (11 ) Unrealized (gain) loss on derivative financial instruments: (Gain) loss recognized on derivative financial instruments $ 7 $ (4 ) $ 1 $ (8 ) Cost of sales Tax effect (3 ) — (1 ) — Income tax expense Net of tax $ 4 $ (4 ) $ — $ (8 ) The Company's realized (gains) and losses on its available-for-sales securities and derivative financial instruments are computed using the specific identification method. Supplemental Equity Information On August 3, 2016, the Company's Board of Directors authorized a cash dividend of $0.31 per share which was paid on October 28, 2016 to shareholders of record as of September 30, 2016. On January 13, 2015, the Company authorized a share repurchase program of up to $500 million of its outstanding common stock. The Company began repurchasing shares on January 30, 2015. From January 30, 2015 through March 2, 2015, the Company repurchased approximately 7.5 million shares for $500 million at an average repurchase price of $66.96 per share. In June 2013, the Company made an equity investment of $40 million in Spinal Modulation, a privately-held company that is focused on the development of an intraspinal neuromodulation therapy that delivers spinal cord stimulation targeting the dorsal root ganglion to manage chronic pain. The investment agreement resulted in a 19% voting equity interest and provided the Company with the exclusive right, but not the obligation, to acquire Spinal Modulation. Additionally, in connection with the investment and contingent acquisition agreement, the Company also entered into an exclusive international distribution agreement, and obtained significant decision-making rights over Spinal Modulation's operations and economic performance. Accordingly, effective June 7, 2013, the Company determined that Spinal Modulation was a variable interest entity for which St. Jude Medical was the primary beneficiary with the financial condition and results of operations of Spinal Modulation included in St. Jude Medical's Condensed Consolidated Financial Statements . During the second quarter of 2015, the Company exercised its exclusive option and paid $173 million to Spinal Modulation’s shareholders to acquire the remaining 81% ownership interest in the company that it did not previously own and accrued $155 million of contingent consideration (see Note 8). The $173 million paid in the second quarter of 2015 was classified as a financing activity in the Condensed Consolidated Statement of Cash Flows . As the Company retained its controlling interest, the payment for the shares and the accrual for contingent consideration resulted in a decrease in shareholders' equity before noncontrolling interest of $297 million and a decrease in noncontrolling interest of $33 million in St. Jude Medical's Condensed Consolidated Balance Sheets . Spinal Modulation's results of operations continue to be included in the Company's Condensed Consolidated Financial Statements . The supplemental equity schedules below present changes in the Company's noncontrolling interest and total shareholders' equity for the nine months ended October 1, 2016 and October 3, 2015 , respectively (in millions): Total Shareholders' Equity Before Total Noncontrolling Noncontrolling Shareholders' For the nine months ended October 1, 2016 Interest Interest Equity Balance at January 2, 2016 $ 4,042 $ — $ 4,042 Net earnings 545 — 545 Cash dividends declared (265 ) — (265 ) Stock-based compensation 83 — 83 Common stock issued under employee stock plans and other, net 73 — 73 Tax benefit from stock plans 8 — 8 Balance at October 1, 2016 $ 4,486 $ — $ 4,486 Total Shareholders' Equity Before Total Noncontrolling Noncontrolling Shareholders' For the nine months ended October 3, 2015 Interest Interest Equity Balance at January 3, 2015 $ 4,199 $ 45 $ 4,244 Net earnings 767 (14 ) 753 Other comprehensive income (loss) (132 ) — (132 ) Cash dividends declared (245 ) — (245 ) Repurchases of common stock (500 ) — (500 ) Stock-based compensation 53 2 55 Common stock issued under employee stock plans and other, net 135 — 135 Tax benefit from stock plans 17 — 17 Additions (purchases) of noncontrolling ownership interests (297 ) (33 ) (330 ) Balance at October 3, 2015 $ 3,997 $ — $ 3,997

Income Taxes

Income Taxes	9 Months Ended
	Oct. 01, 2016
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES As of October 1, 2016 , the Company had $250 million accrued for uncertain tax positions, all of which would affect the Company’s effective tax rate if recognized. Additionally, the Company had $38 million accrued for gross interest and penalties as of October 1, 2016 . At January 2, 2016 , the liability for uncertain tax positions was $338 million and the accrual for gross interest and penalties was $58 million . The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The Company has substantially concluded all material U.S. federal, state, foreign and local income tax matters for all tax years through 2004. During the third quarter of 2016, the Company entered into a settlement agreement with the Internal Revenue Service (IRS), closing its 2008 to 2011 tax examinations. The settlement resulted in a $ 157 million reduction of the Company’s uncertain tax positions during the third quarter of 2016 and reduced its accrual for gross interest by $25 million . The settlement did not result in a material adjustment to tax expense in the third quarter of 2016. The majority of cash owed to the IRS associated with the settlement was paid during the first nine months of 2016 with the remaining amounts expected to be paid to the IRS in the fourth quarter of 2016. The Company's effective income tax rate was 13.5% and 17.6% for the third quarter of 2016 and 2015, respectively, and 16.3% and 12.7% for the nine months ended 2016 and 2015, respectively. The Company’s effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes and foreign taxes that are different than the U.S. federal statutory rate. In addition, the effective tax rate can be impacted each period by discrete income tax factors and events. During the three months ended October 1, 2016, special charges, acquisition-related costs and discrete income tax items unfavorably impacted the effective income tax rate by 0.1 percentage points. During the nine months ended October 1, 2016, special charges, acquisition-related costs, other-than-temporary impairments and discrete income tax items unfavorably impacted the effective income tax rate by 3.1 percentage points. Special charges, acquisition-related costs and discrete income tax items recognized during the third quarter of 2015 unfavorably impacted the effective rate by 1.6 percentage points and favorably impacted the effective rate by 4.2 percentage points during the first nine months of 2015. During the first nine months of 2016, the European Commission concluded that decisions by the tax authorities in Belgium regarding corporate income taxes paid under certain excess profit rulings, including the ruling previously granted to one of the Company’s subsidiaries, did not comply with European Union rules on state aid. Based on the applicability of this conclusion to the Company's 2009 through 2014 tax returns in Belgium, the Company recorded a liability of 43 million Euros ( $48 million as of October 1, 2016) including interest to reserve for this uncertain tax position during the first nine months of 2016.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 01, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The fair value measurement standard applies to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period) and certain financial assets and liabilities that are measured at fair value on a nonrecurring basis. The Company also maintains other financial instruments that approximate their fair value due to their short maturities, and include such instruments as its cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and current and long-term debt obligations. Assets and Liabilities that are Measured at Fair Value on a Recurring Basis The Company's financial assets and liabilities that are measured at fair value on a recurring basis include money-market securities, available-for-sale marketable securities, trading marketable securities, derivative instruments and contingent consideration liabilities. The Company does not have any material nonfinancial assets or liabilities that are measured at fair value on a recurring basis. A summary of the valuation methodologies used for the respective financial assets and liabilities measured at fair value on a recurring basis is as follows: Money-market securities : The Company’s money-market securities include funds that are traded in active markets and are recorded at fair value based upon the quoted market prices. The Company classifies these securities as level 1. Available-for-sale securities : The Company’s available-for-sale securities include publicly-traded equity securities that are traded in active markets and are recorded at fair value based upon the closing stock prices. The Company classifies these securities as level 1. The following table summarizes the components of the balance of the Company’s available-for-sale securities at October 1, 2016 and January 2, 2016 (in millions): October 1, 2016 January 2, 2016 Adjusted cost $ 4 $ 5 Gross unrealized gains 5 6 Gross unrealized losses — (1 ) Fair value $ 9 $ 10 Trading securities : The Company’s trading securities include publicly-traded mutual funds that are traded in active markets and are recorded at fair value based upon quoted market prices of the net asset values of the funds. The Company classifies these securities as level 1. Derivative instruments : Fair values for the Company’s derivative financial instruments are based on quoted market prices of comparable instruments, if available, or more commonly on standard pricing models that use readily observable market parameters from industry standard data providers as their basis. These models reflect contractual terms of the derivatives, including period to maturity and market-based parameters such as foreign currency exchange rates. They do not contain a high level of subjectivity as the techniques used in the models do not require significant judgment and inputs are readily observable from actively quoted markets. The Company classifies these instruments as level 2 (see Note 9). Contingent consideration liabilities: The fair value of the Company's contingent liabilities is initially measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The Company measures the liability on a recurring basis using Level 3 inputs including regulatory approval timing, projected revenues or cash flows, growth rates, discount rates, probabilities of payment and projected payment dates. Projected revenues are based on the Company's most recent internal operating budgets and long-term strategic plans. Changes to any of the inputs may result in significantly higher or lower fair value measurements. A summary of assets and liabilities measured at fair value on a recurring basis at October 1, 2016 and January 2, 2016 is as follows (in millions): Balance Sheet Classification October 1, 2016 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money-market securities Cash and cash equivalents $ 22 $ 22 $ — $ — Available-for-sale securities Other current assets 9 9 — — Foreign currency forward Other current assets 1 — 1 — Trading securities Other assets 322 322 — — Total assets $ 354 $ 353 $ 1 $ — Liabilities Foreign currency forward contracts Other current liabilities $ 32 $ — $ 32 $ — Contingent consideration Other liabilities 40 — — 40 Foreign currency forward contracts Other liabilities 3 — 3 — Total liabilities $ 75 $ — $ 35 $ 40 Balance Sheet Classification January 2, 2016 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money-market securities Cash and cash equivalents $ 273 $ 273 $ — $ — Available-for-sale securities Other current assets 10 10 — — Foreign currency forward contracts Other current assets 14 — 14 — Trading securities Other assets 302 302 — — Foreign currency forward contracts Other assets 2 — 2 — Total assets $ 601 $ 585 $ 16 $ — Liabilities Contingent consideration Other current liabilities $ 118 $ — $ — $ 118 Foreign currency forward contracts Other current liabilities 6 — 6 — Contingent consideration Other liabilities 33 — — 33 Foreign currency forward contracts Other liabilities 3 — 3 — Total liabilities $ 160 $ — $ 9 $ 151 The recurring Level 3 fair value measurements of the Company's contingent consideration liabilities include the following significant unobservable inputs (in millions): Contingent Consideration Liabilities Fair Value as of October 1, 2016 Valuation Technique Unobservable Input Value or Range Spinal Modulation revenue-based milestones and earn-outs $ 7 Monte Carlo Simulation Discount Rates 0.8% - 15.5% Expected Revenue Volatility 25.0% Projected Years of Payments 2017, 2018 Nanostim, Inc. revenue-based milestones 2 Probability Weighted Discounted Cash Flow Discount Rate 5.0% Probability of Payments 10.0% Projected Years of Payments 2017, 2018 Assumed from Thoratec regulatory-based and revenue-based milestones 27 Probability Weighted Discounted Cash Flow Discount Rate 4.3% Probabilities of Payments —% - 90.0% Projected Years of Payments 2018 - 2022 U.S. Distributor revenue-based milestones 4 Probability Weighted Discounted Cash Flow Discount Rates 0.9% - 1.1% Probabilities of Payments —% - 100.0% Projected Years of Payments 2019, 2021 Total contingent consideration liabilities $ 40 Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company's recurring Level 3 fair value measurements (in millions): Nanostim Spinal Modulation Assumed from Thoratec U.S. Distributor Total Balance as of January 3, 2015 $ 50 $ — $ — $ — $ 50 Initial fair value measurement of contingent consideration — 155 — — 155 Liabilities assumed from Thoratec acquisition — — 33 — 33 Change in fair value of contingent consideration (48 ) (33 ) (6 ) — (87 ) Balance as of January 2, 2016 2 122 27 — 151 Change in fair value of contingent consideration — 8 1 — 9 Transfer out of Level 3 fair value measurement due to contractual settlement — (124 ) — — (124 ) Balance as of April 2, 2016 2 6 28 — 36 Change in fair value of contingent consideration — (4 ) (1 ) — (5 ) Balance as of July 2, 2016 2 2 27 — 31 Initial fair value measurement of contingent consideration — — — 4 4 Change in fair value of contingent consideration — 5 — — 5 Balance as of October 1, 2016 $ 2 $ 7 $ 27 $ 4 $ 40 Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis Disclosures are required for certain assets and liabilities that are measured at fair value but are recognized and disclosed at fair value on a nonrecurring basis in periods subsequent to initial recognition. For St. Jude Medical, such measurements of fair value primarily relate to long-lived assets, goodwill, indefinite-lived intangible assets and cost method investments. Other than the items discussed below, there were no other material impairments that were measured at fair value on a nonrecurring basis for the three and nine months ended October 1, 2016 or October 3, 2015 . Long-lived assets: During the three and nine months ended October 1, 2016, the Company recognized $1 million and $6 million , respectively, of fixed asset write-offs primarily associated with projects abandoned as the Company continued to integrate its recent acquisitions. During the three and nine months ended October 3, 2015, the Company recognized $15 million and $17 million of fixed asset write-offs primarily related to fixed asset impairments associated with software development assets no longer expected to be utilized. Typically the Company measures these assets using independent appraisals, market models and discounted cash flow models. However, as these fixed assets had no alternative future use and therefore no discrete future cash flows, the assets were fully impaired. During the third quarter of 2015, the Company also recognized a $2 million impairment charge related to a customer relationship intangible asset. Due to changes in hospital purchasing practices, the Company determined that the intangible asset no longer had any future discrete cash flows and that the asset was fully impaired. Cost method investments: The Company also holds investments in equity securities that are accounted for as cost method investments, which are classified as other assets and measured at fair value on a nonrecurring basis. The carrying value of these investments was $59 million and $80 million as of October 1, 2016 and January 2, 2016 , respectively. During the first nine months of 2016, the Company concluded that adverse regulatory rulings and subsequent operational decisions made by an entity in which the Company had strategic debt and equity investments had an adverse impact on the fair values of those investments. As a result, the Company recognized other-than-temporary impairments of approximately $50 million in other (income) expense in the Condensed Consolidated Statements of Earnings to fully write-down its cost method equity investment and convertible debt investment. The fair value of the Company’s remaining cost method investments was not estimated during the three and nine months ended October 1, 2016 since there were no other identified events or changes in circumstances that may have had a significant adverse effect on the fair value of these investments. Fair Value Measurements of Other Financial Instruments The aggregate fair value of the Company’s fixed-rate senior notes at October 1, 2016 (measured using quoted prices in active markets) was $3,437 million compared to the aggregate carrying value of $3,278 million (inclusive of unamortized debt discounts). The fair value of the Company’s variable-rate debt obligations at October 1, 2016 approximated its aggregate $2,496 million carrying value due to the variable interest rate and short-term nature of these instruments. The Company also had $372 million and $393 million of cash equivalents invested in short-term deposits and interest and non-interest bearing bank accounts at October 1, 2016 and January 2, 2016 , respectively, the cost basis of which approximated the fair value.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Oct. 01, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	DERIVATIVE FINANCIAL INSTRUMENTS The Company uses foreign currency forward contracts, interest rate swaps and interest rate contracts to manage risks generally associated with foreign exchange rate and interest rate fluctuations. The information that follows explains the various types of derivatives financial instruments and how they impacted the Company's financial position and performance. Cash Flow Hedges Foreign exchange forward contracts: During 2015, the Company began to enter into foreign exchange forward contracts to hedge against the effect of exchange rate fluctuations on cash flows denominated in foreign currencies. These transactions are designated as cash flow hedges. The Company hedges its exposure to the variability in future cash flows of forecasted transactions for periods of up to 24 months. The dollar equivalent gross notional amount of the Company’s foreign exchange forward contracts designated as cash flow hedges at October 1, 2016 was approximately $1.0 billion . Hedge ineffectiveness recognized in earnings on cash flow hedges during the three and nine months ended October 1, 2016 and October 3, 2015 was not material. As of October 1, 2016 , the Company had a balance of $27 million associated with the after-tax net unrealized loss position related to foreign currency forward contracts recorded in accumulated other comprehensive income . Based on exchange rates as of October 1, 2016 , the Company expects to reclassify net losses of approximately $22 million after-tax to earnings over the next 12 months contemporaneously with the earnings effects of the related forecasted transactions (with the impact offset by cash flows from the underlying hedged items). The following table provides the (gains) losses related to derivative instruments designated as cash flow hedges for the three and nine months ended October 1, 2016 and October 3, 2015 , including the location in the Condensed Consolidated Statements of Earnings and the Condensed Consolidated Statements of Comprehensive Income (in millions): Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Three Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 1, 2016 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ 7 $ 7 Cost of sales $ — Cost of sales Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Nine Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 1, 2016 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ 51 $ 1 Cost of sales $ — Cost of sales Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Three Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 3, 2015 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ 10 $ (4 ) Cost of sales $ — Cost of sales Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Nine Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 3, 2015 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ (9 ) $ (8 ) Cost of sales $ — Cost of sales Reclassifications from accumulated other comprehensive income into earnings include accumulated (gains) losses on dedesignated hedges at the time earnings are impacted. Derivatives Not Designated as Hedging Instruments Derivatives not designated as hedging instruments include dedesignated foreign currency forward contracts and foreign currency forward contracts that the Company utilizes to economically hedge the foreign currency impact of assets and liabilities denominated in nonfunctional currencies. The dollar equivalent gross notional amount of these forward contracts not designated as hedging instruments totaled approximately $0.2 billion as of October 1, 2016 . The fair value of the Company's outstanding contracts was not material as of October 1, 2016 and January 2, 2016 . The following table provides the (gains) losses related to derivative instruments not designated as hedging instruments, including the location in the Condensed Consolidated Statements of Earnings (in millions): Derivatives Not (Gain) Loss on Derivatives (Gain) Loss on Derivatives Designated as Recognized in Earnings Recognized in Earnings Hedging Three Months Ended Nine Months Ended Instruments October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Location Foreign currency forward contracts $ — $ (3 ) $ 1 $ (11 ) Other (income) expense The net (gains) losses were almost entirely offset by corresponding net (losses) gains on the foreign currency exposures being managed. Location and Fair Value Amount of Derivative Instruments The following table summarizes the fair value of the Company’s derivative instruments and their locations in the Condensed Consolidated Balance Sheets as of October 1, 2016 and January 2, 2016 (in millions): Fair Value of Derivative Instruments October 1, 2016 January 2, 2016 Location Derivatives Designated as Hedging Instruments Foreign currency forward contracts $ 1 $ 14 Other current assets — 2 Other assets (32 ) (6 ) Other current liabilities (3 ) (3 ) Other liabilities Derivatives Not Designated as Hedging Instruments Foreign currency forward contracts — — Other current assets — — Other current liabilities Total $ (34 ) $ 7 Additional information with respect to the fair values of the Company's derivative instruments is included in Note 8. Credit Risk and Offsetting of Assets and Liabilities of Derivative Instruments As of October 1, 2016 , St. Jude Medical, Inc. had International Swaps and Derivatives Association agreements with four applicable banks and financial institutions that contain netting provisions. The following tables provide information as though the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of the netting arrangements with each of the counterparties as of October 1, 2016 and January 2, 2016, respectively (in millions): Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Eligible Offsetting Gross Amount of Recognized Derivative Assets Derivative Liabilities Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of October 1, 2016 Balance Sheet Balance Sheet Received Assets Derivatives subject to master netting agreements $ 1 $ 1 $ — $ — Derivatives not subject to master netting agreements — — Total $ 1 $ 1 $ — $ — Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Gross Amount of Eligible Offsetting Derivative Recognized Liabilities Derivative Assets Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of October 1, 2016 Balance Sheet Balance Sheet Pledged Liabilities Derivatives subject to master netting agreements $ 19 $ 1 $ — $ 18 Derivatives not subject to master netting agreements 16 16 Total $ 35 $ 1 $ — $ 34 Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Eligible Offsetting Gross Amount of Recognized Derivative Assets Derivative Liabilities Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of January 2, 2016 Balance Sheet Balance Sheet Received Assets Derivatives subject to master netting agreements $ 3 $ 1 $ — $ 2 Derivatives not subject to master netting agreements 13 13 Total $ 16 $ 1 $ — $ 15 Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Gross Amount of Eligible Offsetting Derivative Recognized Liabilities Derivative Assets Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of January 2, 2016 Balance Sheet Balance Sheet Pledged Liabilities Derivatives subject to master netting agreements $ 1 $ 1 $ — $ — Derivatives not subject to master netting agreements 8 8 Total $ 9 1 $ — $ 8 For each counterparty, if netted, the Company would offset the asset and liability balances of all derivatives at the end of the reporting period. Derivatives not subject to master netting agreements are not eligible for net presentation. As of both October 1, 2016 and January 2, 2016 , no cash collateral had been received or pledged related to these derivative instruments.

Business Combinations

Business Combinations	9 Months Ended
	Oct. 01, 2016
Business Combinations [Abstract]
Business Combination	BUSINESS COMBINATIONS Fiscal Year 2016 Middle East distributor: In February 2016, the Company acquired certain assets and assumed certain liabilities of a medical device distributor in the Middle East for $19 million of total purchase consideration. The transaction was accounted for as a purchase business combination. The purchase price allocation, which includes customer relationship intangible assets of $7 million and goodwill of $5 million , is considered preliminary, largely with respect to certain tax-related assets and liabilities. During the first nine months of 2016, the Company did not recognize any material adjustments to provisional amounts. U.S. distributor: In September 2016, the Company acquired a medical device distributor in the U.S. for $14 million of total purchase consideration ( $10 million of cash consideration and $4 million of contingent consideration). The transaction was accounted for as a purchase business combination. The purchase price allocation, which includes customer relationship intangible assets of $9 million and goodwill of $5 million , is considered preliminary, largely with respect to certain tax-related liabilities. Fiscal Year 2015 Thoratec: The Company finalized the purchase price allocation during the third quarter of 2016. Based on its evaluation of information about facts and circumstances that existed as of the date Thoratec was acquired, the Company recognized adjustments to provisional amounts that were not material.

Abbott Transaction

Abbott Transaction	9 Months Ended
	Oct. 01, 2016
Subsequent Events [Abstract]
Abbott Transaction	ABBOTT TRANSACTION On April 27, 2016, the Company and Abbott entered into an agreement and plan of merger (the “Merger Agreement”). Under the Merger Agreement generally each outstanding share of the Company’s common stock will be converted into the right to receive (x) $46.75 in cash, without interest thereon, and (y) 0.8708 of a validly issued, fully paid and non-assessable common share of Abbott (such ratio as may be adjusted pursuant to the Merger Agreement), less any applicable withholding taxes. Completion of the merger is subject to customary closing conditions, including (i) adoption of the Merger Agreement by the affirmative vote of the holders of a majority of all outstanding Company common shares, which occurred in connection with the shareholders meeting on October 26, 2016, (ii) effectiveness of the Registration Statement on Form S-4, which was filed with the Securities and Exchange Commission by Abbott in connection with the registration of the Abbott common shares to be issued in the merger and became effective on September 26, 2016, (iii) the expiration of the waiting period applicable under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), and receipt of other specified antitrust approvals, (iv) subject to specified materiality thresholds, the accuracy of the representations and warranties of the other party, (v) the other party having performed in all material respects all of its obligations under the Merger Agreement, (vi) the absence of a material adverse effect, as defined in the Merger Agreement, on the other party, and (vii) the receipt by each party of opinions to the effect that the transaction will be treated as a reorganization for U.S. federal income tax purposes. On July 11, 2016, the Company and Abbott each received a request for additional information (the Second Request) from the United States Federal Trade Commission (FTC) pursuant to the HSR Act, in connection with Abbott’s pending acquisition of the Company. The effect of the Second Request is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and the Company have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC. On October 18, 2016, the Company announced that it and Abbott (together, the Sellers) reached an agreement in principle to sell certain products to Tokyo-based Terumo Corporation (Terumo). The Sellers’ purpose in making this divestiture is to obtain HSR Act approval in the U.S. and additional regulatory approvals in certain foreign jurisdictions that are conditions precedent to completion of the merger. The products that the Sellers propose to sell to Terumo, for cash consideration of approximately $1.12 billion , include the Company’s Angio-Seal TM and FemoSeal TM vascular closure products and Abbott's Vado® Steerable Sheath product. The divestiture is conditioned upon completion of the merger between the Company and Abbott and is expected to close promptly following the merger’s completion .

Basis Of Presentation (Policies

Basis Of Presentation (Policies)	9 Months Ended
	Oct. 01, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements, Policy	New Accounting Pronouncements: The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the Company's financial statements or disclosures. Standard Description Required adoption timing and approach Impact of adoption or other significant matters Standards recently adopted Accounting Standards Update (ASU) No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis The standard affects both the variable interest entity and voting interest entity consolidation models. Annual and interim periods beginning after December 15, 2015, with either retrospective or modified retrospective application permitted. Early adoption is permitted. The Company adopted this ASU in the quarter ended April 2, 2016, using the modified retrospective method. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2015-05, Intangibles--Goodwill and Other--Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement The standard provides guidance to customers about how to account for cloud computing arrangements when such arrangements include software licenses. Annual and interim periods beginning after December 15, 2015, with either prospective or retrospective application permitted. Early adoption was permitted. The Company adopted this ASU in the quarter ended April 2, 2016, using the prospective method. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory The standard requires that inventory within the scope of the guidance be measured at the lower of cost or net realizable value. Annual and interim periods beginning after December 15, 2016, with prospective application required. Early adoption is permitted. The Company adopted this ASU in the quarter ended April 2, 2016. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments The update includes amendments to eight specific cash flow presentation matters, including contingent consideration payments after a business combination. Annual and interim periods beginning after December 15, 2017, with retrospective application required. Early adoption is permitted. The Company adopted this ASU in the interim period ended October 1, 2016. The adoption did not have a material impact on the Company's cash flows. Standards not yet adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will supersede the current revenue recognition requirements. Refer to ASU No. 2015-14 regarding the adoption timing. Either retrospective or modified retrospective application is permitted. The Company plans to adopt this ASU for interim and annual periods beginning after December 15, 2017. The Company is evaluating its approach to the adoption and the potential impact to its results of operations and financial position. ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date The standard defers the effective date of ASU No. 2014-09 to annual and interim periods beginning after December 15, 2017. Early adoption is permitted only as of annual and interim reporting periods beginning after December 15, 2016. Not applicable. Not applicable. ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Among other things, the standard requires certain equity investments to be measured at fair value with changes in fair value recognized in net income, simplifies the impairment assessment of equity investments without readily determinable fair values, and eliminates certain disclosure requirements. Annual and interim periods beginning after December 15, 2017. Early adoption of certain guidance is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position. ASU No. 2016-02, Leases (Topic 842) Among other things, the standard requires recognition of a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position for virtually all leases where we are the lessee. Annual and interim periods beginning after December 15, 2018, with modified retrospective application required. Early adoption is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position. ASU No. 2016-09, Compensation--Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The areas for simplification in this standard involve several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. Annual and interim periods beginning after December 15, 2016, with certain aspects requiring modified retrospective transition, retrospective application, and/or prospective application. Early adoption is permitted if all aspects are adopted simultaneously. The Company is evaluating the timing of adoption and the potential impact to its results of operations, financial position and cash flows. ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Among other things, the standard clarifies the principle for determining whether a good or service is “separately identifiable” from other promises in the contract and, therefore, should be accounted for separately. It also clarifies that entities are not required to identify promised goods or services that are immaterial in the context of the contract. Refer to ASU No. 2015-14 regarding the adoption timing. Either retrospective or modified retrospective application is permitted. The Company plans to adopt this ASU for interim and annual periods beginning after December 15, 2017. The Company is evaluating its approach to the adoption and the potential impact to its results of operations and financial position. ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory The standard requires the income tax consequences of an intra-entity transfer of an asset other than inventory to be recognized when the transfer occurs. Annual and interim periods beginning after December 15, 2017, with modified retrospective application required. Early adoption is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position, which is expected to be material.

Basis Of Presentation (Tables)

Basis Of Presentation (Tables)	9 Months Ended
	Oct. 01, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of New Accounting Pronouncements	New Accounting Pronouncements: The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the Company's financial statements or disclosures. Standard Description Required adoption timing and approach Impact of adoption or other significant matters Standards recently adopted Accounting Standards Update (ASU) No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis The standard affects both the variable interest entity and voting interest entity consolidation models. Annual and interim periods beginning after December 15, 2015, with either retrospective or modified retrospective application permitted. Early adoption is permitted. The Company adopted this ASU in the quarter ended April 2, 2016, using the modified retrospective method. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2015-05, Intangibles--Goodwill and Other--Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement The standard provides guidance to customers about how to account for cloud computing arrangements when such arrangements include software licenses. Annual and interim periods beginning after December 15, 2015, with either prospective or retrospective application permitted. Early adoption was permitted. The Company adopted this ASU in the quarter ended April 2, 2016, using the prospective method. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory The standard requires that inventory within the scope of the guidance be measured at the lower of cost or net realizable value. Annual and interim periods beginning after December 15, 2016, with prospective application required. Early adoption is permitted. The Company adopted this ASU in the quarter ended April 2, 2016. The adoption did not have a material impact on the Company's results of operations or financial position. ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments The update includes amendments to eight specific cash flow presentation matters, including contingent consideration payments after a business combination. Annual and interim periods beginning after December 15, 2017, with retrospective application required. Early adoption is permitted. The Company adopted this ASU in the interim period ended October 1, 2016. The adoption did not have a material impact on the Company's cash flows. Standards not yet adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will supersede the current revenue recognition requirements. Refer to ASU No. 2015-14 regarding the adoption timing. Either retrospective or modified retrospective application is permitted. The Company plans to adopt this ASU for interim and annual periods beginning after December 15, 2017. The Company is evaluating its approach to the adoption and the potential impact to its results of operations and financial position. ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date The standard defers the effective date of ASU No. 2014-09 to annual and interim periods beginning after December 15, 2017. Early adoption is permitted only as of annual and interim reporting periods beginning after December 15, 2016. Not applicable. Not applicable. ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Among other things, the standard requires certain equity investments to be measured at fair value with changes in fair value recognized in net income, simplifies the impairment assessment of equity investments without readily determinable fair values, and eliminates certain disclosure requirements. Annual and interim periods beginning after December 15, 2017. Early adoption of certain guidance is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position. ASU No. 2016-02, Leases (Topic 842) Among other things, the standard requires recognition of a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position for virtually all leases where we are the lessee. Annual and interim periods beginning after December 15, 2018, with modified retrospective application required. Early adoption is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position. ASU No. 2016-09, Compensation--Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The areas for simplification in this standard involve several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. Annual and interim periods beginning after December 15, 2016, with certain aspects requiring modified retrospective transition, retrospective application, and/or prospective application. Early adoption is permitted if all aspects are adopted simultaneously. The Company is evaluating the timing of adoption and the potential impact to its results of operations, financial position and cash flows. ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Among other things, the standard clarifies the principle for determining whether a good or service is “separately identifiable” from other promises in the contract and, therefore, should be accounted for separately. It also clarifies that entities are not required to identify promised goods or services that are immaterial in the context of the contract. Refer to ASU No. 2015-14 regarding the adoption timing. Either retrospective or modified retrospective application is permitted. The Company plans to adopt this ASU for interim and annual periods beginning after December 15, 2017. The Company is evaluating its approach to the adoption and the potential impact to its results of operations and financial position. ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory The standard requires the income tax consequences of an intra-entity transfer of an asset other than inventory to be recognized when the transfer occurs. Annual and interim periods beginning after December 15, 2017, with modified retrospective application required. Early adoption is permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial position, which is expected to be material.

Debt (Tables)

Debt (Tables)	9 Months Ended
	Oct. 01, 2016
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	The carrying value of the Company’s debt, including debt issuance costs, discounts or premiums consisted of the following (in millions): October 1, 2016 January 2, 2016 Term Loan Due 2020 $ 2,336 $ 2,093 2016 Senior Notes — 500 2018 Senior Notes 497 496 2020 Senior Notes 497 496 2023 Senior Notes 893 892 2025 Senior Notes 495 494 2043 Senior Notes 689 689 Yen-denominated Senior Notes Due 2017 81 68 Yen-denominated Senior Notes Due 2020 126 106 Yen-denominated credit facilities 64 54 Commercial paper borrowings 96 504 Total debt 5,774 6,392 Less: current debt obligations 371 1,163 Long-term debt $ 5,403 $ 5,229
Schedule of Maturities of Long-term Debt	Contractual maturities of the Company's debt for the next five fiscal years and thereafter, excluding any debt issuance costs, discounts or premiums, as of October 1, 2016 were as follows (in millions): Remainder of 2016 2017 2018 2019 2020 After 2020 Future minimum principal payments $ 128 $ 275 $ 598 $ 227 $ 2,481 $ 2,100

Commitments And Contingencies (

Commitments And Contingencies (Tables)	9 Months Ended
	Oct. 01, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule Of Product Warranty Liability	Changes in the Company’s product warranty liability during the three and nine months ended October 1, 2016 and October 3, 2015 were as follows (in millions): Three Months Ended Nine Months Ended October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Balance at beginning of period $ 25 $ 29 $ 31 $ 35 Warranty expense (benefit) recognized 4 — 5 (4 ) Warranty credits issued (4 ) (1 ) (11 ) (3 ) Balance at end of period $ 25 $ 28 $ 25 $ 28

Special Charges (Tables)

Special Charges (Tables)	9 Months Ended
	Oct. 01, 2016
2016 Initiatives
Restructuring Cost and Reserve
Summary Of Activity Related To Special Charge Restructuring Accrual	A summary of the activity related to the 2016 Initiatives accrual is as follows (in millions): Employee Inventory Fixed Other Restructuring Costs Total Balance at January 3, 2015 $ — $ — $ — $ — $ — Cost of sales special charges 9 1 1 1 12 Special charges 22 — — — 22 Non-cash charges used — (1 ) (1 ) — (2 ) Cash payments (2 ) — — (1 ) (3 ) Balance at January 2, 2016 29 — — — 29 Cost of sales special charges — 2 1 1 4 Special charges 11 — 4 5 20 Non-cash charges used — (2 ) (5 ) — (7 ) Cash payments (32 ) — — (5 ) (37 ) Balance at April 2, 2016 8 — — 1 9 Cost of sales special charges — — — 2 2 Special charges 6 — — 4 10 Cash payments (6 ) — — (4 ) (10 ) Balance at July 2, 2016 8 — — 3 11 Cost of sales special charges — — — 2 2 Special charges 2 — 1 1 4 Non-cash charges used — — (1 ) — (1 ) Cash payments (3 ) — — (3 ) (6 ) Balance at October 1, 2016 $ 7 $ — $ — $ 3 $ 10
Manufacturing and Supply Chain Optimization Plan
Restructuring Cost and Reserve
Summary Of Activity Related To Special Charge Restructuring Accrual	A summary of the activity related to the Manufacturing and Supply Chain Optimization Plan accrual is as follows (in millions): Employee Inventory Fixed Other Restructuring Costs Total Balance at January 3, 2015 $ 14 $ — $ — $ 6 $ 20 Cost of sales special charges 4 3 15 7 29 Special charges 20 — — 29 49 Non-cash charges used — (3 ) (15 ) — (18 ) Cash payments (27 ) — — (35 ) (62 ) Balance at January 2, 2016 11 — — 6 17 Cost of sales special charges — — — 1 1 Cash payments (3 ) — — (6 ) (9 ) Balance at April 2, 2016 8 — — 1 9 Cost of sales special charges — — — 1 1 Special charges — — — 1 1 Cash payments (3 ) — — (2 ) (5 ) Balance at July 2, 2016 5 — — 1 6 Special charges — — — 1 1 Cash payments (2 ) — — (1 ) (3 ) Balance at October 1, 2016 $ 3 $ — $ — $ 1 $ 4
2012 Business Realignment Restructuring Plan
Restructuring Cost and Reserve
Summary Of Activity Related To Special Charge Restructuring Accrual	A summary of the activity related to the 2012 Business Realignment Plan accrual is as follows (in millions): Employee Termination Costs Inventory Charges Fixed Asset Charges Other Restructuring Costs Total Balance at January 3, 2015 $ 26 $ — $ — $ 12 $ 38 Cost of sales special charges 2 3 — — 5 Special charges 2 — 2 5 9 Non-cash charges used — (3 ) (2 ) — (5 ) Cash payments (25 ) — — (10 ) (35 ) Foreign exchange rate impact (2 ) — — — (2 ) Balance at January 2, 2016 3 — — 7 10 Cost of sales special charges — (1 ) — (1 ) (2 ) Non-cash charges used — 1 — — 1 Balance at April 2, 2016 3 — — 6 9 Cash payments (1 ) — — — (1 ) Balance at July 2, 2016 2 — — 6 8 Cost of sales special charges — (2 ) — — (2 ) Special charges (1 ) — — — (1 ) Non-cash charges used — 2 — — 2 Cash payments (1 ) — — — (1 ) Balance at October 1, 2016 $ — $ — $ — $ 6 $ 6

Net Earnings Per Share (Tables)

Net Earnings Per Share (Tables)	9 Months Ended
	Oct. 01, 2016
Earnings Per Share [Abstract]
Schedule Of Computation Of Basic And Diluted Net Earnings Per Share	The table below sets forth the computation of basic and diluted net earnings per share attributable to St. Jude Medical, Inc. (in millions, except per share amounts): Three Months Ended Nine Months Ended October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Numerator: Net earnings attributable to St. Jude Medical, Inc. $ 212 $ 215 $ 545 $ 767 Denominator: Basic weighted average shares outstanding 285.2 282.2 284.3 282.1 Dilution associated with stock-based compensation plans 4.8 4.1 3.9 4.2 Diluted weighted average shares outstanding 290.0 286.3 288.2 286.3 Basic net earnings per share attributable to St. Jude Medical, Inc. $ 0.74 $ 0.76 $ 1.92 $ 2.72 Diluted net earnings per share attributable to St. Jude Medical, Inc. $ 0.73 $ 0.75 $ 1.89 $ 2.68 Anti-dilutive shares of common stock excluded from diluted net earnings per share attributable to St. Jude Medical, Inc. — 2.6 4.1 3.1

Accumulated Other Comprehensi25

Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Information (Tables)	9 Months Ended
	Oct. 01, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The tables below present the changes in each component of accumulated other comprehensive income, net of tax, including other comprehensive income and reclassifications out of accumulated other comprehensive income into net earnings for the three and nine months ended October 1, 2016 and October 3, 2015 , respectively (in millions): Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the three months ended sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of July 2, 2016 $ 4 $ (23 ) $ (328 ) $ (347 ) Other comprehensive income (loss) before reclassifications (1 ) (4 ) 3 (2 ) Amounts reclassified to net earnings from accumulated other comprehensive income — 4 — 4 Other comprehensive income (loss) (1 ) — 3 2 Accumulated other comprehensive income (loss) as of October 1, 2016 $ 3 $ (23 ) $ (325 ) $ (345 ) The tables below present the changes in each component of accumulated other comprehensive income, net of tax, including other comprehensive income and reclassifications out of accumulated other comprehensive income into net earnings for the three and nine months ended October 1, 2016 and October 3, 2015 , respectively (in millions): Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the three months ended sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of July 2, 2016 $ 4 $ (23 ) $ (328 ) $ (347 ) Other comprehensive income (loss) before reclassifications (1 ) (4 ) 3 (2 ) Amounts reclassified to net earnings from accumulated other comprehensive income — 4 — 4 Other comprehensive income (loss) (1 ) — 3 2 Accumulated other comprehensive income (loss) as of October 1, 2016 $ 3 $ (23 ) $ (325 ) $ (345 ) Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the nine months ended sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of January 2, 2016 $ 3 $ 11 $ (359 ) $ (345 ) Other comprehensive income (loss) before reclassifications — (34 ) 34 — Amounts reclassified to net earnings from accumulated other comprehensive income — — — — Other comprehensive income (loss) — (34 ) 34 — Accumulated other comprehensive income (loss) as of October 1, 2016 $ 3 $ (23 ) $ (325 ) $ (345 ) Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the three months ended October 3, 2015 sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of July 4, 2015 $ 12 $ 15 $ (288 ) $ (261 ) Other comprehensive income (loss) before reclassifications (1 ) (7 ) (25 ) (33 ) Amounts reclassified to net earnings from accumulated other comprehensive income (7 ) (4 ) — (11 ) Other comprehensive income (loss) (8 ) (11 ) (25 ) (44 ) Accumulated other comprehensive income (loss) as of October 3, 2015 $ 4 $ 4 $ (313 ) $ (305 ) Unrealized Gain (Loss) On Unrealized Foreign Accumulated Available-for- Gain (Loss) On Currency Other For the nine months ended October 3, 2015 sale Derivative Instruments translation adjustment Comprehensive Income (Loss) Accumulated other comprehensive income (loss) as of January 3, 2015 $ 15 $ 3 $ (191 ) $ (173 ) Other comprehensive income (loss) before reclassifications — 9 (122 ) (113 ) Amounts reclassified to net earnings from accumulated other comprehensive income (11 ) (8 ) — (19 ) Other comprehensive income (loss) (11 ) 1 (122 ) (132 ) Accumulated other comprehensive income (loss) as of October 3, 2015 $ 4 $ 4 $ (313 ) $ (305 )
Reclassification out of Accumulated Other Comprehensive Income	The following table provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Condensed Consolidated Statements of Earnings during the three and nine months ended October 1, 2016 and October 3, 2015 , respectively (in millions): Details about Amount reclassified from accumulated other comprehensive income accumulated other Three Months Ended Nine Months Ended comprehensive income components October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Statements of Earnings Classification Unrealized (gain) loss on available-for-sale securities: (Gain) loss on sale of available-for-sale securities $ — $ (11 ) $ — $ (18 ) Other (income) expense Tax effect — 4 — 7 Income tax expense Net of tax $ — $ (7 ) $ — $ (11 ) Unrealized (gain) loss on derivative financial instruments: (Gain) loss recognized on derivative financial instruments $ 7 $ (4 ) $ 1 $ (8 ) Cost of sales Tax effect (3 ) — (1 ) — Income tax expense Net of tax $ 4 $ (4 ) $ — $ (8 )
Schedule of Noncontrolling Interest	The supplemental equity schedules below present changes in the Company's noncontrolling interest and total shareholders' equity for the nine months ended October 1, 2016 and October 3, 2015 , respectively (in millions): Total Shareholders' Equity Before Total Noncontrolling Noncontrolling Shareholders' For the nine months ended October 1, 2016 Interest Interest Equity Balance at January 2, 2016 $ 4,042 $ — $ 4,042 Net earnings 545 — 545 Cash dividends declared (265 ) — (265 ) Stock-based compensation 83 — 83 Common stock issued under employee stock plans and other, net 73 — 73 Tax benefit from stock plans 8 — 8 Balance at October 1, 2016 $ 4,486 $ — $ 4,486 Total Shareholders' Equity Before Total Noncontrolling Noncontrolling Shareholders' For the nine months ended October 3, 2015 Interest Interest Equity Balance at January 3, 2015 $ 4,199 $ 45 $ 4,244 Net earnings 767 (14 ) 753 Other comprehensive income (loss) (132 ) — (132 ) Cash dividends declared (245 ) — (245 ) Repurchases of common stock (500 ) — (500 ) Stock-based compensation 53 2 55 Common stock issued under employee stock plans and other, net 135 — 135 Tax benefit from stock plans 17 — 17 Additions (purchases) of noncontrolling ownership interests (297 ) (33 ) (330 ) Balance at October 3, 2015 $ 3,997 $ — $ 3,997

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 01, 2016
Fair Value Disclosures [Abstract]
Summary of Components of Available-For-Sale Securities	The following table summarizes the components of the balance of the Company’s available-for-sale securities at October 1, 2016 and January 2, 2016 (in millions): October 1, 2016 January 2, 2016 Adjusted cost $ 4 $ 5 Gross unrealized gains 5 6 Gross unrealized losses — (1 ) Fair value $ 9 $ 10
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	A summary of assets and liabilities measured at fair value on a recurring basis at October 1, 2016 and January 2, 2016 is as follows (in millions): Balance Sheet Classification October 1, 2016 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money-market securities Cash and cash equivalents $ 22 $ 22 $ — $ — Available-for-sale securities Other current assets 9 9 — — Foreign currency forward Other current assets 1 — 1 — Trading securities Other assets 322 322 — — Total assets $ 354 $ 353 $ 1 $ — Liabilities Foreign currency forward contracts Other current liabilities $ 32 $ — $ 32 $ — Contingent consideration Other liabilities 40 — — 40 Foreign currency forward contracts Other liabilities 3 — 3 — Total liabilities $ 75 $ — $ 35 $ 40 Balance Sheet Classification January 2, 2016 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money-market securities Cash and cash equivalents $ 273 $ 273 $ — $ — Available-for-sale securities Other current assets 10 10 — — Foreign currency forward contracts Other current assets 14 — 14 — Trading securities Other assets 302 302 — — Foreign currency forward contracts Other assets 2 — 2 — Total assets $ 601 $ 585 $ 16 $ — Liabilities Contingent consideration Other current liabilities $ 118 $ — $ — $ 118 Foreign currency forward contracts Other current liabilities 6 — 6 — Contingent consideration Other liabilities 33 — — 33 Foreign currency forward contracts Other liabilities 3 — 3 — Total liabilities $ 160 $ — $ 9 $ 151
Summary of Level 3 Fair Value Measurements of Contingent Consideration Liability	The recurring Level 3 fair value measurements of the Company's contingent consideration liabilities include the following significant unobservable inputs (in millions): Contingent Consideration Liabilities Fair Value as of October 1, 2016 Valuation Technique Unobservable Input Value or Range Spinal Modulation revenue-based milestones and earn-outs $ 7 Monte Carlo Simulation Discount Rates 0.8% - 15.5% Expected Revenue Volatility 25.0% Projected Years of Payments 2017, 2018 Nanostim, Inc. revenue-based milestones 2 Probability Weighted Discounted Cash Flow Discount Rate 5.0% Probability of Payments 10.0% Projected Years of Payments 2017, 2018 Assumed from Thoratec regulatory-based and revenue-based milestones 27 Probability Weighted Discounted Cash Flow Discount Rate 4.3% Probabilities of Payments —% - 90.0% Projected Years of Payments 2018 - 2022 U.S. Distributor revenue-based milestones 4 Probability Weighted Discounted Cash Flow Discount Rates 0.9% - 1.1% Probabilities of Payments —% - 100.0% Projected Years of Payments 2019, 2021 Total contingent consideration liabilities $ 40
Unobservable Input Reconciliation of Contingent Consideration Liability	Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company's recurring Level 3 fair value measurements (in millions): Nanostim Spinal Modulation Assumed from Thoratec U.S. Distributor Total Balance as of January 3, 2015 $ 50 $ — $ — $ — $ 50 Initial fair value measurement of contingent consideration — 155 — — 155 Liabilities assumed from Thoratec acquisition — — 33 — 33 Change in fair value of contingent consideration (48 ) (33 ) (6 ) — (87 ) Balance as of January 2, 2016 2 122 27 — 151 Change in fair value of contingent consideration — 8 1 — 9 Transfer out of Level 3 fair value measurement due to contractual settlement — (124 ) — — (124 ) Balance as of April 2, 2016 2 6 28 — 36 Change in fair value of contingent consideration — (4 ) (1 ) — (5 ) Balance as of July 2, 2016 2 2 27 — 31 Initial fair value measurement of contingent consideration — — — 4 4 Change in fair value of contingent consideration — 5 — — 5 Balance as of October 1, 2016 $ 2 $ 7 $ 27 $ 4 $ 40

Derivative Financial Instrume27

Derivative Financial Instruments (Tables)	9 Months Ended
	Oct. 01, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Derivative Instruments (Gain) Loss	The following table provides the (gains) losses related to derivative instruments designated as cash flow hedges for the three and nine months ended October 1, 2016 and October 3, 2015 , including the location in the Condensed Consolidated Statements of Earnings and the Condensed Consolidated Statements of Comprehensive Income (in millions): Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Three Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 1, 2016 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ 7 $ 7 Cost of sales $ — Cost of sales Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Nine Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 1, 2016 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ 51 $ 1 Cost of sales $ — Cost of sales Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Three Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 3, 2015 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ 10 $ (4 ) Cost of sales $ — Cost of sales Pre-tax (Gain) Loss Recognized Ineffective Portion of Pre-tax (Gain) Loss in Earnings on Effective Portion (Gain) Loss on Derivative Recognized in Other of Derivative as a Result of and Amount Excluded from Nine Comprehensive Reclassification from Effectiveness Testing months Income on Effective Accumulated Other Recognized ended Portion of Derivative Comprehensive Income in Earnings October 3, 2015 Amount Amount Location Amount Location Derivatives in Cash Flow Hedging Relationships Foreign currency forward contracts $ (9 ) $ (8 ) Cost of sales $ — Cost of sales
Derivative Instruments, Gain (Loss), Not Designated as Hedging Instrument	The following table provides the (gains) losses related to derivative instruments not designated as hedging instruments, including the location in the Condensed Consolidated Statements of Earnings (in millions): Derivatives Not (Gain) Loss on Derivatives (Gain) Loss on Derivatives Designated as Recognized in Earnings Recognized in Earnings Hedging Three Months Ended Nine Months Ended Instruments October 1, 2016 October 3, 2015 October 1, 2016 October 3, 2015 Location Foreign currency forward contracts $ — $ (3 ) $ 1 $ (11 ) Other (income) expense
Schedule of Fair Value of Derivative Instruments in Statement of Financial Position	The following table summarizes the fair value of the Company’s derivative instruments and their locations in the Condensed Consolidated Balance Sheets as of October 1, 2016 and January 2, 2016 (in millions): Fair Value of Derivative Instruments October 1, 2016 January 2, 2016 Location Derivatives Designated as Hedging Instruments Foreign currency forward contracts $ 1 $ 14 Other current assets — 2 Other assets (32 ) (6 ) Other current liabilities (3 ) (3 ) Other liabilities Derivatives Not Designated as Hedging Instruments Foreign currency forward contracts — — Other current assets — — Other current liabilities Total $ (34 ) $ 7
Schedule of Offsetting Derivative Assets	The following tables provide information as though the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of the netting arrangements with each of the counterparties as of October 1, 2016 and January 2, 2016, respectively (in millions): Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Eligible Offsetting Gross Amount of Recognized Derivative Assets Derivative Liabilities Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of October 1, 2016 Balance Sheet Balance Sheet Received Assets Derivatives subject to master netting agreements $ 1 $ 1 $ — $ — Derivatives not subject to master netting agreements — — Total $ 1 $ 1 $ — $ — Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Gross Amount of Eligible Offsetting Derivative Recognized Liabilities Derivative Assets Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of October 1, 2016 Balance Sheet Balance Sheet Pledged Liabilities Derivatives subject to master netting agreements $ 19 $ 1 $ — $ 18 Derivatives not subject to master netting agreements 16 16 Total $ 35 $ 1 $ — $ 34 Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Eligible Offsetting Gross Amount of Recognized Derivative Assets Derivative Liabilities Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of January 2, 2016 Balance Sheet Balance Sheet Received Assets Derivatives subject to master netting agreements $ 3 $ 1 $ — $ 2 Derivatives not subject to master netting agreements 13 13 Total $ 16 $ 1 $ — $ 15 Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements Gross Amount of Gross Amount of Eligible Offsetting Derivative Recognized Liabilities Derivative Assets Presented in the Presented in the Net Condensed Condensed Cash Amount of Consolidated Consolidated Collateral Derivative Derivatives as of January 2, 2016 Balance Sheet Balance Sheet Pledged Liabilities Derivatives subject to master netting agreements $ 1 $ 1 $ — $ — Derivatives not subject to master netting agreements 8 8 Total $ 9 1 $ — $ 8

Basis Of Presentation (Details)

Basis Of Presentation (Details)	9 Months Ended
	Oct. 01, 2016Area
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of principal product categories	5

Debt - Schedule Of Long-Term De

Debt - Schedule Of Long-Term Debt (Details) - USD ($) $ in Millions	Oct. 01, 2016	Jan. 02, 2016
Debt Instrument
Total debt	$ 5,774	$ 6,392
Less: current debt obligations	371	1,163
Long-term debt	5,403	5,229
Term Loan Due 2020 | Loans Payable
Debt Instrument
Total debt	2,336	2,093
2016 Senior Notes | Senior Notes
Debt Instrument
Total debt	0	500
2018 Senior Notes | Senior Notes
Debt Instrument
Total debt	497	496
2020 Senior Notes | Senior Notes
Debt Instrument
Total debt	497	496
2023 Senior Notes | Senior Notes
Debt Instrument
Total debt	893	892
2025 Senior Notes | Senior Notes
Debt Instrument
Total debt	495	494
2043 Senior Notes | Senior Notes
Debt Instrument
Total debt	689	689
Yen-denominated Senior Notes Due 2017 | Senior Notes
Debt Instrument
Total debt	81	68
Yen-denominated Senior Notes Due 2020 | Senior Notes
Debt Instrument
Total debt	126	106
Yen-denominated credit facilities | Line of Credit
Debt Instrument
Total debt	64	54
Commercial paper borrowings | Commercial Paper
Debt Instrument
Total debt	$ 96	$ 504

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Long-term Debt (Details) $ in Millions	Oct. 01, 2016USD ($)
Debt Disclosure [Abstract]
Remainder of 2016	$ 128
2,017	275
2,018	598
2,019	227
2,020	2,481
After 2,020	$ 2,100

Debt (Details)

Debt (Details) - 9 months ended Oct. 01, 2016 ¥ in Millions	USD ($)	JPY (¥)	USD ($)
Debt Instrument
Repayments of commercial paper	$ 408,000,000
2016 Senior Notes | Senior Notes
Debt Instrument
Face amount of debt			$ 500,000,000
Debt instrument term	5 years
Stated percentage		2.50%	2.50%
Term loan due August 2020 | Loans Payable
Debt Instrument
Face amount of debt			$ 2,600,000,000
Debt instrument term	5 years
Remaining borrowing capacity			500,000,000
Principal payment	$ 92,000,000
Prepaid amount of debt	$ 167,000,000
Yen Denominated Credit Facilities, Due in March 2017 | Line of Credit
Debt Instrument
Line of credit		¥ 3,250	32,000,000
Extension period	1 year
Basis spread on variable rate	0.25%
Yen Denominated Credit Facilities, Due in June 2017 | Line of Credit
Debt Instrument
Line of credit		¥ 3,250	$ 32,000,000
Extension period	1 year
Basis spread on variable rate	0.27%

Commitments And Contingencies32

Commitments And Contingencies (Details) $ in Thousands	Jul. 05, 2016case	Mar. 31, 2013case	Jul. 02, 2016USD ($)
December 2012 Securities Litigation
Loss Contingencies [Line Items]
Number of cases consolidated | case		2
Litigation settlement amount | $			$ 39,250
Insurance recoveries amount | $			$ 39,250
Abbott Merger Lawsuits
Loss Contingencies [Line Items]
Number of cases consolidated | case	2

Commitments And Contingencies -

Commitments And Contingencies - Schedule Of Product Warranty Liability (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at beginning of period	$ 25	$ 29	$ 31	$ 35
Warranty expense (benefit) recognized	4	0	5	(4)
Warranty credits issued	(4)	(1)	(11)	(3)
Balance at end of period	$ 25	$ 28	$ 25	$ 28

Special Charges (Details)

Special Charges (Details) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 01, 2016USD ($)	Oct. 03, 2015USD ($)	Oct. 01, 2016USD ($)settlement	Oct. 03, 2015USD ($)	Dec. 29, 2012division
Purchased In-Process Research And Development (IPR&D) And Special Charges
Litigation charges	$ 3
Number of legal settlements | settlement			4
Restructuring-related costs			$ 3
Field Action Costs
Purchased In-Process Research And Development (IPR&D) And Special Charges
Litigation charges			6	$ 14
Loss (benefit) contingency in period	25		28
Field Action Costs | Cost of sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Loss (benefit) contingency in period	26			(7)
Field Action Costs, Scrapped Inventory and Warranty Costs | Cost of sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Loss (benefit) contingency in period			5
Field Action Costs, Salvaged Inventory | Cost of sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Loss (benefit) contingency in period	(1)		(3)	(5)
Field Action Costs, Lower Than Expected Direct Recall Costs | Cost of sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Loss (benefit) contingency in period				(2)
Separate Legal Cases in Current Year
Purchased In-Process Research And Development (IPR&D) And Special Charges
Litigation settlement gains (losses)			19
Product Liability Claim
Purchased In-Process Research And Development (IPR&D) And Special Charges
Litigation charges		$ 1
March 2010 Securities Class Action
Purchased In-Process Research And Development (IPR&D) And Special Charges
Insurance recoveries				$ 10
Customer relationship
Purchased In-Process Research And Development (IPR&D) And Special Charges
Intangible asset impairment charges		$ 2
2012 Business Realignment Restructuring Plan
Purchased In-Process Research And Development (IPR&D) And Special Charges
Number of operating divisions | division					2
Minimum | 2016 Initiatives
Purchased In-Process Research And Development (IPR&D) And Special Charges
Expected cost remaining	5		5
Maximum | 2016 Initiatives
Purchased In-Process Research And Development (IPR&D) And Special Charges
Expected cost remaining	$ 10		$ 10

Special Charges - Summary Of Ac

Special Charges - Summary Of Activity Related To Special Charge Restructuring Accrual (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Oct. 01, 2016	Jul. 02, 2016	Apr. 02, 2016	Jan. 02, 2016
2016 Initiatives
Restructuring Reserve [Roll Forward]
Balance at beginning	$ 11	$ 9	$ 29	$ 0
Non-cash charges used	(1)		(7)	(2)
Cash payments	(6)	(10)	(37)	(3)
Balance at ending	10	11	9	29
2016 Initiatives | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Balance at beginning	8	8	29	0
Non-cash charges used	0		0	0
Cash payments	(3)	(6)	(32)	(2)
Balance at ending	7	8	8	29
2016 Initiatives | Inventory Charges
Restructuring Reserve [Roll Forward]
Balance at beginning	0	0	0	0
Non-cash charges used	0		(2)	(1)
Cash payments	0	0	0	0
Balance at ending	0	0	0	0
2016 Initiatives | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Balance at beginning	0	0	0	0
Non-cash charges used	(1)		(5)	(1)
Cash payments	0	0	0	0
Balance at ending	0	0	0	0
2016 Initiatives | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Balance at beginning	3	1	0	0
Non-cash charges used	0		0	0
Cash payments	(3)	(4)	(5)	(1)
Balance at ending	3	3	1	0
2016 Initiatives | Cost of sales
Restructuring Reserve [Roll Forward]
Restructuring Charges	2	2	4	12
2016 Initiatives | Cost of sales | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	0	0	0	9
2016 Initiatives | Cost of sales | Inventory Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0	0	2	1
2016 Initiatives | Cost of sales | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0	0	1	1
2016 Initiatives | Cost of sales | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	2	2	1	1
2016 Initiatives | Operating Expense
Restructuring Reserve [Roll Forward]
Restructuring Charges	4	10	20	22
2016 Initiatives | Operating Expense | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	2	6	11	22
2016 Initiatives | Operating Expense | Inventory Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0	0	0	0
2016 Initiatives | Operating Expense | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	1	0	4	0
2016 Initiatives | Operating Expense | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	1	4	5	0
Manufacturing and Supply Chain Optimization Plan
Restructuring Reserve [Roll Forward]
Balance at beginning	6	9	17	20
Non-cash charges used				(18)
Cash payments	(3)	(5)	(9)	(62)
Balance at ending	4	6	9	17
Manufacturing and Supply Chain Optimization Plan | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Balance at beginning	5	8	11	14
Non-cash charges used				0
Cash payments	(2)	(3)	(3)	(27)
Balance at ending	3	5	8	11
Manufacturing and Supply Chain Optimization Plan | Inventory Charges
Restructuring Reserve [Roll Forward]
Balance at beginning	0	0	0	0
Non-cash charges used				(3)
Cash payments	0	0	0	0
Balance at ending	0	0	0	0
Manufacturing and Supply Chain Optimization Plan | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Balance at beginning	0	0	0	0
Non-cash charges used				(15)
Cash payments	0	0	0	0
Balance at ending	0	0	0	0
Manufacturing and Supply Chain Optimization Plan | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Balance at beginning	1	1	6	6
Non-cash charges used				0
Cash payments	(1)	(2)	(6)	(35)
Balance at ending	1	1	1	6
Manufacturing and Supply Chain Optimization Plan | Cost of sales
Restructuring Reserve [Roll Forward]
Restructuring Charges		1	1	29
Manufacturing and Supply Chain Optimization Plan | Cost of sales | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges		0	0	4
Manufacturing and Supply Chain Optimization Plan | Cost of sales | Inventory Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges		0	0	3
Manufacturing and Supply Chain Optimization Plan | Cost of sales | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges		0	0	15
Manufacturing and Supply Chain Optimization Plan | Cost of sales | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges		1	1	7
Manufacturing and Supply Chain Optimization Plan | Operating Expense
Restructuring Reserve [Roll Forward]
Restructuring Charges	1	1		49
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	0	0		20
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Inventory Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0	0		0
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0	0		0
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	1	1		29
2012 Business Realignment Restructuring Plan
Restructuring Reserve [Roll Forward]
Balance at beginning	8	9	10	38
Non-cash charges used	2		1	(5)
Cash payments	(1)	(1)		(35)
Foreign exchange rate impact				(2)
Balance at ending	6	8	9	10
2012 Business Realignment Restructuring Plan | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Balance at beginning	2	3	3	26
Non-cash charges used	0		0	0
Cash payments	(1)	(1)		(25)
Foreign exchange rate impact				(2)
Balance at ending	0	2	3	3
2012 Business Realignment Restructuring Plan | Inventory Charges
Restructuring Reserve [Roll Forward]
Balance at beginning	0	0	0	0
Non-cash charges used	2		1	(3)
Cash payments	0	0		0
Foreign exchange rate impact				0
Balance at ending	0	0	0	0
2012 Business Realignment Restructuring Plan | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Balance at beginning	0	0	0	0
Non-cash charges used	0		0	(2)
Cash payments	0	0		0
Foreign exchange rate impact				0
Balance at ending	0	0	0	0
2012 Business Realignment Restructuring Plan | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Balance at beginning	6	6	7	12
Non-cash charges used	0		0	0
Cash payments	0	0		(10)
Foreign exchange rate impact				0
Balance at ending	6	$ 6	6	7
2012 Business Realignment Restructuring Plan | Cost of sales
Restructuring Reserve [Roll Forward]
Restructuring Charges	(2)		(2)	5
2012 Business Realignment Restructuring Plan | Cost of sales | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	0		0	2
2012 Business Realignment Restructuring Plan | Cost of sales | Inventory Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	(2)		(1)	3
2012 Business Realignment Restructuring Plan | Cost of sales | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0		0	0
2012 Business Realignment Restructuring Plan | Cost of sales | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	0		$ (1)	0
2012 Business Realignment Restructuring Plan | Operating Expense
Restructuring Reserve [Roll Forward]
Restructuring Charges	(1)			9
2012 Business Realignment Restructuring Plan | Operating Expense | Employee Termination Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	(1)			2
2012 Business Realignment Restructuring Plan | Operating Expense | Inventory Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0			0
2012 Business Realignment Restructuring Plan | Operating Expense | Fixed Asset Charges
Restructuring Reserve [Roll Forward]
Restructuring Charges	0			2
2012 Business Realignment Restructuring Plan | Operating Expense | Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Charges	$ 0			$ 5

Net Earnings Per Share - Schedu

Net Earnings Per Share - Schedule of Computation of Basic and Diluted Net Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Earnings Per Share [Abstract]
Net earnings attributable to St. Jude Medical, Inc.	$ 212	$ 215	$ 545	$ 767
Basic weighted average shares outstanding	285.2	282.2	284.3	282.1
Dilution associated with stock-based compensation plans (in shares)	4.8	4.1	3.9	4.2
Diluted weighted average shares outstanding	290	286.3	288.2	286.3
Basic net earnings per share attributable to St. Jude Medical, Inc. (USD per share)	$ 0.74	$ 0.76	$ 1.92	$ 2.72
Diluted net earnings per share attributable to St. Jude Medical, Inc. (USD per share)	$ 0.73	$ 0.75	$ 1.89	$ 2.68
Anti-dilutive shares of common stock excluded from diluted net earnings per share attributable to St. Jude Medical, Inc. (in shares)	0	2.6	4.1	3.1

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Information - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance			$ 4,042	$ 4,244
Other comprehensive income (loss), net of tax	$ 2	$ (44)	0	(132)
Ending Balance	4,486	3,997	4,486	3,997
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(347)	(261)	(345)	(173)
Other comprehensive income (loss) before reclassifications	(2)	(33)	0	(113)
Amounts reclassified to net earnings from accumulated other comprehensive income	4	(11)	0	(19)
Other comprehensive income (loss), net of tax	2	(44)	0	(132)
Ending Balance	(345)	(305)	(345)	(305)
Unrealized gain (loss) on available-for-sale securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	4	12	3	15
Other comprehensive income (loss) before reclassifications	(1)	(1)	0	0
Amounts reclassified to net earnings from accumulated other comprehensive income	0	(7)	0	(11)
Other comprehensive income (loss), net of tax	(1)	(8)	0	(11)
Ending Balance	3	4	3	4
Unrealized gain (loss) on derivative instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(23)	15	11	3
Other comprehensive income (loss) before reclassifications	(4)	(7)	(34)	9
Amounts reclassified to net earnings from accumulated other comprehensive income	4	(4)	0	(8)
Other comprehensive income (loss), net of tax	0	(11)	(34)	1
Ending Balance	(23)	4	(23)	4
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(328)	(288)	(359)	(191)
Other comprehensive income (loss) before reclassifications	3	(25)	34	(122)
Amounts reclassified to net earnings from accumulated other comprehensive income	0	0	0	0
Other comprehensive income (loss), net of tax	3	(25)	34	(122)
Ending Balance	$ (325)	$ (313)	$ (325)	$ (313)

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Information - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other (income) expense	$ 2	$ 12	$ 58	$ 9
Cost of sales	495	425	1,478	1,244
Income tax expense	33	46	106	110
Net earnings attributable to St. Jude Medical, Inc.	(212)	(215)	(545)	(767)
Unrealized gain (loss) on available-for-sale securities | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other (income) expense	0	(11)	0	(18)
Income tax expense	0	4	0	7
Net earnings attributable to St. Jude Medical, Inc.	0	(7)	0	(11)
Unrealized gain (loss) on derivative instruments | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales	7	(4)	1	(8)
Income tax expense	(3)	0	(1)	0
Net earnings attributable to St. Jude Medical, Inc.	$ 4	$ (4)	$ 0	$ (8)

Accumulated Other Comprehensi39

Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Information (Details) - USD ($) $ / shares in Units, shares in Millions	Aug. 03, 2016	Mar. 02, 2015	Oct. 01, 2016	Oct. 03, 2015	Jul. 04, 2015	Oct. 01, 2016	Oct. 03, 2015	Jan. 13, 2015	Jun. 07, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Cash dividends declared per share (USD per share)	$ 0.31		$ 0.31	$ 0.29		$ 0.93	$ 0.87
Authorized amount								$ 500,000,000
Shares repurchased, shares		7.5
Shares repurchased, value		$ 500,000,000					$ 500,000,000
Average repurchase price (USD per share)		$ 66.96
Business Combination, Separately Recognized Transactions [Line Items]
Additions (purchases) of noncontrolling ownership interests							$ 330,000,000
Spinal Modulation
Business Combination, Separately Recognized Transactions [Line Items]
Equity investment									$ 40,000,000
Voting equity interest									19.00%
Additions (purchases) of noncontrolling ownership interests					$ 173,000,000
Ownership percentage by noncontrolling owners					81.00%
Contingent consideration					$ 155,000,000
Increase (decrease) in stockholders' equity					(297,000,000)
Increase (decrease) in noncontrolling interest					$ (33,000,000)

Accumulated Other Comprehensi40

Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Information- Supplemental Equity Schedule (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 02, 2015	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance				$ 4,042	$ 4,244
Net earnings		$ 212	$ 215	545	753
Other comprehensive income (loss)		2	(44)	0	(132)
Cash dividends declared				(265)	(245)
Repurchases of common stock	$ (500)				(500)
Stock-based compensation				83	55
Common stock issued under employee stock plans and other, net				73	135
Tax benefit from stock plans				8	17
Additions (purchases) of noncontrolling ownership interests					(330)
Ending Balance		4,486	3,997	4,486	3,997
Shareholders' Equity Before Noncontrolling Interest
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance				4,042	4,199
Net earnings				545	767
Other comprehensive income (loss)					(132)
Cash dividends declared				(265)	(245)
Repurchases of common stock					(500)
Stock-based compensation				83	53
Common stock issued under employee stock plans and other, net				73	135
Tax benefit from stock plans				8	17
Additions (purchases) of noncontrolling ownership interests					(297)
Ending Balance		4,486	3,997	4,486	3,997
Noncontrolling Interest
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance				0	45
Net earnings				0	(14)
Other comprehensive income (loss)					0
Cash dividends declared				0	0
Repurchases of common stock					0
Stock-based compensation				0	2
Common stock issued under employee stock plans and other, net				0	0
Tax benefit from stock plans				0	0
Additions (purchases) of noncontrolling ownership interests					(33)
Ending Balance		$ 0	$ 0	$ 0	$ 0

Income Taxes (Details)

Income Taxes (Details) € in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016USD ($)	Oct. 03, 2015	Oct. 01, 2016USD ($)	Oct. 03, 2015	Oct. 01, 2016EUR (€)	Jan. 02, 2016USD ($)
Income Tax Examination [Line Items]
Unrecognized tax benefits	$ 250		$ 250			$ 338
Accrued interest and penalties	$ 38		$ 38			$ 58
Effective income tax rate reconciliation, percent	13.50%	17.60%	16.30%	12.70%
Special charges, acquisition-related costs, and discrete tax items impact of effective income tax rate	(0.10%)	(1.60%)	(3.10%)	4.20%
Liability for uncertain tax positions	$ 48		$ 48		€ 43
IRS
Income Tax Examination [Line Items]
Reduction of uncertain tax positions from settlements	157
Reduction of accrued interest from settlements	$ 25		$ 25

Fair Value Measurements - Summa

Fair Value Measurements - Summary Of Components Of Available-For-Sale Securities (Details) - USD ($) $ in Millions	Oct. 01, 2016	Jan. 02, 2016
Fair Value Disclosures [Abstract]
Adjusted cost	$ 4	$ 5
Gross unrealized gains	5	6
Gross unrealized losses	0	(1)
Fair value	$ 9	$ 10

Fair Value Measurements - Sum43

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value, Recurring Basis (Details) - USD ($) $ in Millions	Oct. 01, 2016	Jan. 02, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	$ 9	$ 10
Derivative assets, foreign currency forward contracts	0	15
Derivative liabilities, foreign currency forward contracts	34	8
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	354	601
Total liabilities	75	160
Recurring | Cash and cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	22	273
Recurring | Other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	9	10
Derivative assets, foreign currency forward contracts	1	14
Recurring | Other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, foreign currency forward contracts		2
Trading securities	322	302
Recurring | Other current liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		118
Derivative liabilities, foreign currency forward contracts	32	6
Recurring | Other liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	40	33
Derivative liabilities, foreign currency forward contracts	3	3
Recurring | Quoted Prices In Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	353	585
Total liabilities	0	0
Recurring | Quoted Prices In Active Markets (Level 1) | Cash and cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	22	273
Recurring | Quoted Prices In Active Markets (Level 1) | Other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	9	10
Derivative assets, foreign currency forward contracts	0	0
Recurring | Quoted Prices In Active Markets (Level 1) | Other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, foreign currency forward contracts		0
Trading securities	322	302
Recurring | Quoted Prices In Active Markets (Level 1) | Other current liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		0
Derivative liabilities, foreign currency forward contracts	0	0
Recurring | Quoted Prices In Active Markets (Level 1) | Other liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Derivative liabilities, foreign currency forward contracts	0	0
Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	1	16
Total liabilities	35	9
Recurring | Significant Other Observable Inputs (Level 2) | Cash and cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	0	0
Recurring | Significant Other Observable Inputs (Level 2) | Other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Derivative assets, foreign currency forward contracts	1	14
Recurring | Significant Other Observable Inputs (Level 2) | Other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, foreign currency forward contracts		2
Trading securities	0	0
Recurring | Significant Other Observable Inputs (Level 2) | Other current liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		0
Derivative liabilities, foreign currency forward contracts	32	6
Recurring | Significant Other Observable Inputs (Level 2) | Other liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Derivative liabilities, foreign currency forward contracts	3	3
Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	40	151
Recurring | Significant Unobservable Inputs (Level 3) | Cash and cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	0	0
Recurring | Significant Unobservable Inputs (Level 3) | Other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Derivative assets, foreign currency forward contracts	0	0
Recurring | Significant Unobservable Inputs (Level 3) | Other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, foreign currency forward contracts		0
Trading securities	0	0
Recurring | Significant Unobservable Inputs (Level 3) | Other current liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		118
Derivative liabilities, foreign currency forward contracts	0	0
Recurring | Significant Unobservable Inputs (Level 3) | Other liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	40	33
Derivative liabilities, foreign currency forward contracts	$ 0	$ 0

Fair Value Measurements - Sum44

Fair Value Measurements - Summary of Level 3 Fair Value Measurements of Contingent Consideration (Details) - Fair Value, Inputs, Level 3 - USD ($) $ in Millions	9 Months Ended
	Oct. 01, 2016	Jul. 02, 2016	Apr. 02, 2016	Jan. 02, 2016	Jan. 03, 2015
Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 40	$ 31	$ 36	$ 151	$ 50
Spinal Modulation | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 7	2	6	122	0
Spinal Modulation | Monte Carlo Simulation
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Expected revenue volatility	25.00%
Spinal Modulation | Monte Carlo Simulation | Minimum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Discount Rate	0.80%
Spinal Modulation | Monte Carlo Simulation | Maximum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Discount Rate	15.50%
Spinal Modulation | Monte Carlo Simulation | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 7
Nanostim | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 2	2	2	2	50
Nanostim | Probability Weighted Discounted Cash Flow
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Discount Rate	5.00%
Probability of Payments	10.00%
Nanostim | Probability Weighted Discounted Cash Flow | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 2
Thoratec | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 27	27	28	27	0
Thoratec | Probability Weighted Discounted Cash Flow
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Discount Rate	4.30%
Thoratec | Probability Weighted Discounted Cash Flow | Minimum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Probability of Payments	0.00%
Thoratec | Probability Weighted Discounted Cash Flow | Maximum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Probability of Payments	90.00%
Thoratec | Probability Weighted Discounted Cash Flow | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 27
U.S. Distributor | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 4	$ 0	$ 0	$ 0	$ 0
U.S. Distributor | Probability Weighted Discounted Cash Flow | Minimum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Discount Rate	0.90%
Probability of Payments	0.00%
U.S. Distributor | Probability Weighted Discounted Cash Flow | Maximum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Discount Rate	1.10%
Probability of Payments	100.00%
U.S. Distributor | Probability Weighted Discounted Cash Flow | Contingent Consideration Liabilities
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent Consideration Liabilities	$ 4

Fair Value Measurements - Unobs

Fair Value Measurements - Unobservable Input Reconciliation of Contingent Consideration Liability (Details) - Fair Value, Inputs, Level 3 - Contingent Consideration Liabilities - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Oct. 01, 2016	Jul. 02, 2016	Apr. 02, 2016	Jan. 02, 2016
Contingent Consideration Liability [Roll Forward]
Beginning balance	$ 31	$ 36	$ 151	$ 50
Initial fair value measurement of contingent consideration	4			155
Liabilities assumed from Thoratec acquisition				33
Change in fair value of contingent consideration	5	(5)	9	(87)
Transfer out of Level 3 fair value measurement due to contractual settlement			(124)
Ending balance	40	31	36	151
Nanostim
Contingent Consideration Liability [Roll Forward]
Beginning balance	2	2	2	50
Initial fair value measurement of contingent consideration	0			0
Liabilities assumed from Thoratec acquisition				0
Change in fair value of contingent consideration	0	0	0	(48)
Transfer out of Level 3 fair value measurement due to contractual settlement			0
Ending balance	2	2	2	2
Spinal Modulation
Contingent Consideration Liability [Roll Forward]
Beginning balance	2	6	122	0
Initial fair value measurement of contingent consideration	0			155
Liabilities assumed from Thoratec acquisition				0
Change in fair value of contingent consideration	5	(4)	8	(33)
Transfer out of Level 3 fair value measurement due to contractual settlement			(124)
Ending balance	7	2	6	122
Thoratec
Contingent Consideration Liability [Roll Forward]
Beginning balance	27	28	27	0
Initial fair value measurement of contingent consideration	0			0
Liabilities assumed from Thoratec acquisition				33
Change in fair value of contingent consideration	0	(1)	1	(6)
Transfer out of Level 3 fair value measurement due to contractual settlement			0
Ending balance	27	27	28	27
U.S. Distributor
Contingent Consideration Liability [Roll Forward]
Beginning balance	0	0	0	0
Initial fair value measurement of contingent consideration	4			0
Liabilities assumed from Thoratec acquisition				0
Change in fair value of contingent consideration	0	0	0	0
Transfer out of Level 3 fair value measurement due to contractual settlement			0
Ending balance	$ 4	$ 0	$ 0	$ 0

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015	Jan. 02, 2016
Fair Value Inputs, Liabilities, Quantitative Information
Cost method investments	$ 59		$ 59		$ 80
Fixed rate debt obligations fair value disclosure	3,437		3,437
Fixed rate debt obligations carrying value	3,278		3,278
Other debt carrying value	2,496		2,496
Cash equivalents at carrying value excluding money market securities	372		372		$ 393
Other (income) expense
Fair Value Inputs, Liabilities, Quantitative Information
Other-than-temporary impairments			50
Customer relationship
Fair Value Inputs, Liabilities, Quantitative Information
Impairment of intangible assets		$ 2
Fixed Asset Charges | 2016 Initiatives
Fair Value Inputs, Liabilities, Quantitative Information
Fixed asset charges	$ 1		$ 6
Fixed Asset Charges | Manufacturing and Supply Chain Optimization Plan
Fair Value Inputs, Liabilities, Quantitative Information
Fixed asset charges		$ 15		$ 17

Derivative Financial Instrume47

Derivative Financial Instruments (Details) $ in Millions	9 Months Ended
	Oct. 01, 2016USD ($)bank
Derivatives, Fair Value [Line Items]
After-tax net unrealized loss related to foreign currency forward contracts recorded in accumulated other comprehensive income	$ 27
Unrealized losses expected to be reclassed to earnings over the next 12 months	$ 22
Number of applicable banks and financial institutions that contain netting provisions | bank	4
Foreign currency forward contracts | Designated as Hedging Instrument | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Maximum length of time hedged in cash flow hedge	24 months
Gross notional amount of derivative	$ 1,000
Foreign currency forward contracts | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross notional amount of derivative	$ 200

Derivative Financial Instrume48

Derivative Financial Instruments - Summary of Derivative Instruments (Gain) Loss (Details) - Foreign currency forward contracts - Designated as Hedging Instrument - Cash Flow Hedging - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Derivative Instruments, (Gain) Loss [Line Items]
Pre-tax (gain) loss recognized in other comprehensive income on effective portion of derivative	$ 7	$ 10	$ 51	$ (9)
Cost of sales
Derivative Instruments, (Gain) Loss [Line Items]
Pre-tax (Gain) Loss Recognized in Earnings on Effective Portion of Derivative as a Result of Reclassification from Accumulated Other Comprehensive Income	7	(4)	1	(8)
Ineffective Portion of (Gain) Loss on Derivative and Excluded from Effectiveness Testing Recognized in Earnings	$ 0	$ 0	$ 0	$ 0

Derivative Financial Instrume49

Derivative Financial Instruments - Summary of Derivative Instruments (Gain) Loss, Not Designated as Hedging (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Oct. 03, 2015	Oct. 01, 2016	Oct. 03, 2015
Foreign currency forward contracts | Other (income) expense | Not Designated as Hedging Instrument
Derivative Instruments, (Gain) Loss [Line Items]
(Gain) Loss on Derivatives Recognized in Earnings	$ 0	$ (3)	$ 1	$ (11)

Derivative Financial Instrume50

Derivative Financial Instruments - Schedule of Fair Value of Derivative Instruments (Details) - USD ($) $ in Millions	Oct. 01, 2016	Jan. 02, 2016
Derivatives, Fair Value [Line Items]
Derivative asset	$ 1	$ 3
Derivative liability	(19)	(1)
Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Total	(34)	7
Foreign currency forward contracts | Designated as Hedging Instrument | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset	1	14
Foreign currency forward contracts | Designated as Hedging Instrument | Other assets
Derivatives, Fair Value [Line Items]
Derivative asset	0	2
Foreign currency forward contracts | Designated as Hedging Instrument | Other current liabilities
Derivatives, Fair Value [Line Items]
Derivative liability	(32)	(6)
Foreign currency forward contracts | Designated as Hedging Instrument | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative liability	(3)	(3)
Foreign currency forward contracts | Not Designated as Hedging Instrument | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset	0	0
Foreign currency forward contracts | Not Designated as Hedging Instrument | Other current liabilities
Derivatives, Fair Value [Line Items]
Derivative liability	$ 0	$ 0

Derivative Financial Instrume51

Derivative Financial Instruments - Schedule of Offsetting Derivative Assets (Details) - USD ($) $ in Millions	Oct. 01, 2016	Jan. 02, 2016
Assets
Gross amount of derivatives subject to master netting agreements	$ 1	$ 3
Gross amount of derivatives not subject to master netting agreements	0	13
Gross amount of derivatives	1	16
Gross amount of eligible offsetting recognized derivative liabilities	1	1
Cash collateral received	0	0
Net amount of derivatives	0	2
Total	0	15
Liabilities
Gross amount of derivatives subject to master netting agreements	19	1
Gross amount of derivatives not subject to master netting agreements	16	8
Gross amount of derivatives	35	9
Gross amount of eligible offsetting recognized derivative assets	1	1
Cash collateral pledged	0	0
Net amount of derivatives	18	0
Total	$ 34	$ 8

Business Combinations (Details)

Business Combinations (Details) - USD ($) $ in Millions	1 Months Ended
	Sep. 30, 2016	Feb. 29, 2016	Oct. 01, 2016	Jan. 02, 2016
Business Acquisition [Line Items]
Goodwill			$ 5,678	$ 5,651
Middle East distributor
Business Acquisition [Line Items]
Total purchase consideration		$ 19
Goodwill		5
U.S. Distributor
Business Acquisition [Line Items]
Total purchase consideration	$ 14
Payments to acquire businesses	10
Contingent consideration, liability	4
Goodwill	5
Customer relationship | Middle East distributor
Business Acquisition [Line Items]
Intangible assets from business combination		$ 7
Customer relationship | U.S. Distributor
Business Acquisition [Line Items]
Intangible assets from business combination	$ 9

Abbott Transaction (Details)

Abbott Transaction (Details) $ / shares in Units, $ in Millions	Oct. 18, 2016USD ($)	Jul. 11, 2016	Apr. 27, 2016$ / shares
Subsequent Event [Line Items]
Business acquisition, share price (USD / share) | $ / shares			$ 46.75
Business acquisition, share ratio			0.8708
Business acquisition, extended waiting period		30 days
Disposal Group, Disposed of by Sale | Terumo | Subsequent Event
Subsequent Event [Line Items]
Proceeds from divestiture | $	$ 1,120